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There is currently considerable uncertainty surrounding the future of HIV/AIDS funding.  
With pressures from the recent financial crisis forcing donors to carefully review their 
spending priorities, some have claimed, firstly, that HIV/AIDS receives too much money 
relative to its disease burden and, secondly, that the future costs of treating those with the 
disease will become unmanageable.  This paper seeks to clarify each of these two areas in the 
following ways.  Firstly, it examines the proportionality of HIV/AIDS funding to its disease 
burden in the year 2008 by measuring that percentage of total health expenditure spent on 
HIV/AIDS against that percentage of total disease burden attributable to the disease.  It pays 
particular attention to a recently raised issue; namely, whether using OECD or UNAIDS data 
has any significant effect on the number of countries spending above or below the level that 
is proportional to their HIV/AIDS disease burdens.  This occupies the main part of the paper.  
Results indicate that the majority of countries in the dataset ‗overspend‘ on HIV/AIDS 
relative to the most commonly employed measure of disease burden, the Disability Adjusted 
Life Year (DALY).  This result, however, belies the fact that global ‗underspending‘ is far 
more severe than ‗overspending‘; while most countries ‗overspend‘, the total amount in 
surplus of proportionality in overspending countries is dwarfed by the total amount needed to 
reach proportionality in underspending ones.  In other words, global HIV/AIDS resources are 
inadequate to bring all countries‘ spending on the disease in line with their disease burdens.  
 
Secondly, the paper critiques the assumptions of a recently released AIDS costing model 
(‗AIDSCost‘) and compares its outputs for South Africa to those of ASSA2003, South 
Africa‘s most highly developed AIDS modelling tool, for the period 2007-2016 as a test of 
the former‘s accuracy.  Results indicate that, even when applying a number of different 
antiretroviral therapy (ART) coverage and costing scenarios, AIDSCost overestimates the 
future burden of ART by as much as 100%.  Though the model‘s costing function is 
disputable, the most serious errors underlie the calculation of vital outputs on which costing 
depends, most notably AIDS death rates, the number of those on ART and HIV prevalence.  
Accordingly, it is argued that the model should be subjected to thorough refinement before it 
is used by anyone.  Further, it is argued that AIDSCost co-author Mead Over, in employing 
the model to show that ‗ballooning‘ ART burdens will overwhelm US aid budgets, generates 
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List of commonly used acronyms and key terms 
 
 
AIDS  Acquired Immunodeficiency Syndrome 
ART  Antiretroviral Therapy 
CRS  Creditor Reporting System [OECD official development assistance database] 
DAC  Development Assistance Committee [of OECD]  
DALY  Disability Adjusted Life Year [Measure of disease burden] 
HIV  Human Immunodeficiency Virus 
NASA  National AIDS Spending Assessment [UNAIDS data on AIDS spending] 
NHA  National Health Accounts [WHO data on total health expenditure] 
ODA  Official Development Assistance 
OECD  Organisation for Economic Cooperation and Development 
PEPFAR President‘s Emergency Plan for AIDS Relief [USA] 
TB  Tuberculosis 
UNAIDS Joint United Nations Program on HIV/AIDS 
WHO  World Health Organisation 
 
 
Proportionality Refers to the share of total health expenditure spent on AIDS relative 
to the share of total disease burden accounted for by AIDS 
 
AIDS sick Refers to those individuals who require or are eligible for ART.  In 
South Africa, these are individuals whose CD4 (a type of white blood 
cell that fights infection) counts are below 200 
 
Disease burden Broadly defined, the harm caused to human beings by disease.  
Measures of disease burden aim to quantify this harm and do so in 
various ways.  Some consider only lives lost to a disease, while others 
(like the DALY) also consider the morbidity/disability associated with 
it 
 
Disbursements Funding actually available for spending (usually measured in a 
particular year) 
 
Commitments Funding guaranteed by donors (may be ‗disbursed‘ over a number of 
years) 
 
Overspending Refers to an instance of spending on AIDS above the level implied by 















    
expenditure spent on AIDS in a country exceeds the share of total 
DALYs attributable to AIDS.  This does not imply that a country is 
spending too much on AIDS, but rather indicates its spending relative 
to a particular measure      
 
Underspending As above, but refers to an instance of spending on AIDS below the 
level implied by proportionality 
 
Reallocation Used to refer to those funds that would have to be transferred from 
AIDS (to other diseases) in order for strict proportionality to hold 
within a given country 
 
Debate in Science Refers to a 2010 debate between Nattrass & Gonsalves and Bongaarts 
& Over on the issue of proportionality (specifically regarding data 
sources) in the journal Science (volume 330, pages 174-178).   
  
AIDS cost modeling  Using mathematical modeling techniques to project the future financial 
resource requirements of HIV/AIDS interventions (including 
prevention, treatment and healthcare infrastructure). 
  
AIDSCost An AIDS costing model developed by the Centre for Global 
Development and co-authored by Owen McCarthy and Mead Over.  It 
has been designed to forecast the future financial burden of 
antiretroviral therapy, both globally and by country, up until the year 
2050.  
 
ASSA2003 An epidemiological model of the HIV/AIDS virus in South Africa 
developed by the Actuarial Society of South Africa.  This model uses a 
wide variety of data applicable to South Africa and is calibrated to fit 















    
Introduction 
 
The global catastrophe that is HIV/AIDS (henceforth AIDS) has created a powerful and 
dedicated machinery of activism that, since the 1980s, has roused far-reaching international, 
multi-sectoral responses to the epidemic (see Fabj and Sobnosky, 1995; Epstein, 1998; 
Heywood and Altman, 2000 and Grebe, 2008).  This machinery has been very good at 
mobilising resources – especially in the last decade or so.  In 2009, disbursements (that is, 
actual resources available for spending) by donor governments totaled approximately $7.6 
billion (Kates et al, 2009: 2).  77% of this was provided bilaterally (country to country), but a 
sizeable proportion (23%) found its way through multilateral agencies (UNAIDS, 2010a: 
152).  Moreover, a powerful and sustained surge in international funding took place between 
2002 and 2008: 
 
Figure I.1: International AIDS assistance (disbursements), 2002-2009 (billions of US$) 
 
 
      Source: Adapted from Kates et al, 2009: 4 
 
The United States (US) has been the most powerful driving force behind the AIDS response.   
It first provided funding for global AIDS interventions in 1986, and since then its 
international efforts in this regard have been steadily expanding – both absolutely and as a 
share of the total US AIDS budget (Kaiser Family Foundation, 2010: 2).  In 2009 the US 








































    
public sector spending, private sector spending and philanthropic contributions) for AIDS.  It 
leads decisively: the next highest contributor was the United Kingdom, which contributed 
10.2% and 4.7% respectively (Kates et al, 2010: 2).  The US‘s PEPFAR (President‘s 
Emergency Plan for AIDS Relief) programme, created in 2003, pledged $15 billion over five 
years to combat AIDS, malaria and tuberculosis (Kates and Lief, 2006: 7).  An additional $48 
billion was authorized in 2008 for the period 2008-2013 (PEPFAR, 2011: online).  The US, 
through PEPFAR, is also the heftiest contributor to the Global Fund to fight AIDS, 
Tuberculosis and Malaria (Kates et al, 2010: 7; Kaiser Family Foundation, 2010: 2).   
 
Resources are, however, still inadequate.  In many low and middle income countries, funding 
gaps show themselves daily in the empty spaces where drugs, doctors and testing centres 
should be.  Even given massive injections of funding, and including all possible sources of 
funding, UNAIDS – together with the Kaiser Family Foundation - estimated that 
approximately $7.7 billion in additional funding was needed in 2009 for a comprehensive 
response (prevention, treatment, infrastructure and human resources) to the epidemic in low 
and middle income countries (Kates et al, 2010: 9).  Approximately 33.3 million people were 
still living with the disease come the end of 2009, a 27% increase from the 1999 level of 26.2 
million.  Though this has partly to do with vastly expanded access to life-saving and life-
prolonging antiretroviral therapy (ART), a large proportion of those urgently needing drugs 
are not getting them.  In 2009 in Sub-Saharan Africa, only 37% of those eligible for treatment 
were able to access it, while this proportion was 42% in South and Central America and 19% 
in Eastern Europe and Central Asia (UNAIDS, 2010a: 96).  Globally, approximately 9.8 
million people did not have access to the treatment they needed in 2009.  Many people dying 
of AIDS (1.8 million in 2009), thus, do so far from the threshold at which modern medicine 
can keep them alive (UNAIDS, 2010a: 19).   
 
It is clear that the large international funding network that supports the AIDS response is not 
large enough to get help to all those that need it.  Still, its scale has placed AIDS funding 
under the spotlight.  Recently, a question has been put to the responders: ‗are you not perhaps 
spending too much on this disease‘?  It seems a callous question to some, especially 
considering the many AIDS sufferers still awaiting treatment, but several factors have urged 
its asking.  Firstly, the 2008 financial crisis has placed severe pressure on all governments, 
donors included, and spending priorities have been placed under close scrutiny (see 















    
assistance for AIDS leveled off – even dropping slightly – between 2008 and 2009.  The US 
Federal Budget for 2011 cut 5% in contributions to the Global Fund from 2010.  While it 
called for a 2% increase in overall global contributions to AIDS relief, relative to previous 
year-on-year increases this is a near flat-lining of funds: 
 
Figure I.2: Percentage increases in US Federal funding for global HIV/AIDS relief, Federal 
Years 2006-2011    
/AIDS relief, Federal Years 2006-2011 
 
    Source: Calculated from Kaiser Family Foundation, 2010: 3 
 
Elsewhere, strong concern has been voiced by AIDS relief workers, Non Governmental 
Organisations (NGOs) and various media commentators over the scaling back of funding 
commitments that will see many aid-dependant relief projects severely compromised (see, for 
example, Guardian, 2011: online; PULSE, 2011: online; Health Gap, 2011: online; and Heal 
Africa, 2011: online).   
 
Secondly, the donor attention paid to AIDS has raised concerns over whether a zero-sum 
game exists among diseases, wherein high spending on AIDS, given finite resources, leads to 
the neglect of other illnesses (see, for example, England, 2007 and Bongaarts and Over, 
2010).  While AIDS is a vast and dangerous epidemic, so the argument goes, the funding it 
receives should be linked to its disease burden – in other words, what causes the most harm 
should get the most money.  There are various other vast and dangerous conditions that, 


















































    
respiratory conditions, malaria, pneumonia, diarrheal illnesses and various tropical diseases 
have been flagged as significant but underfunded conditions in low and middle income 
countries (Shiffman, 2006; Moran et al, 2009; Liese and Schubert, 2009).  Such concern has 
motivated comparisons of that proportion of total health spending spent on AIDS (both 
globally and regionally) with that proportion of total disease burden accounted for by AIDS 
(see, for example, Amico et al, 2010 and Nattrass and Gonsalves, 2010).  These 
‗proportionality‘ exercises aim for clarity on whether AIDS is unfairly favoured in terms of 
global health spending.  Finally, alarm has been raised about the future costs of AIDS.  While 
much has been done, much has still to be done, and a series of mathematical models have 
been created to gauge the future financial burden of the epidemic.  Authors such as Over 
(2008) and Hecht et al (2009) have used such models to voice concerns that AIDS funding 
commitments will soon overwhelm global health budgets should the epidemic continue on its 
current path.  In particular, Over (2008) has argued for a shift from treatment to prevention, 
partly on the basis that the former will become prohibitively expensive.   
 
Both AIDS modeling and exercises in ‗proportionality‘, however, remain very contentious.  
There is considerable debate about whether AIDS is, in fact, receiving too much or too little 
money relative to its disease burden.  The issue came to the fore in a recent (2010) issue of 
the journal Science.  Nattrass and Gonsalves (2010: 175) used 2007 UNAIDS data to argue 
that the proportion of total health spending spent on AIDS was greater than the disease‘s 
share of the disease burden (as given by Disability Adjusted Life Years [DALYs], a measure 
that shall be thoroughly discussed in Chapter 2) in a small minority of countries.  Bongaarts 
and Over (2010: 177), however, argued that using data from the Organisation for Economic 
Cooperation and Development (OECD) would produce a more reliable and different 
conclusion.  The issue has yet to be resolved.  Further, AIDS modeling exercises produce 
impressively complex outputs relating to future costs, but many of these have yet to be tested 
against reliable alternative estimations based on real data.  The numbers underlying our 
conception of the future costs of AIDS are accepted largely on faith that the modelers and 
their models are working.         
 
Given the gravity of the issues at hand, there is a need for clarity within the two areas above, 
both of which have become considerably blurry and both of which, despite this blurriness, 
have played active parts in the debate about whether AIDS is receiving ‗too much‘ money.  















    
examines the proportionality of AIDS funding to its disease burden in the year 2008 (the 
most recent available data) by measuring that percentage of total health expenditure spent on 
HIV/AIDS against that percentage of total disease burden attributable to the disease.  
Particular attention is paid to the issue raised in Science; namely, whether using OECD or 
UNAIDS data has any significant effect on the number of countries spending above or below 
the level that is proportional to their AIDS disease burdens.  Proportionality is the area of 
most complexity and controversy and constitutes the main focus of the paper.  The paper then 
goes on to critique the assumptions of a recently released AIDS costing model (‗AIDSCost‘) 
and compares its outputs for South Africa to those of the country‘s most sophisticated AIDS 
projection model, ASSA2003.  The choice of model is motivated, as we shall see, by the fact 
that its chief creator has used (and continues to use) its outputs to make strong claims 
regarding policies focused on treatment, and also by the fact that the creators of the model 
have solicited critique of it for the purposes of improvement.  As we shall see, the proven 
reliability of ASSA2003 (which uses a much wider range of inputs and has been calibrated to 
the South African epidemic) allows us to generate such critique by comparing its outputs with 
those of AIDSCost.  
 
Chapter 1 summarises the main contributions to the literature and expands on the need for 
further research in each of the two areas (proportionality and AIDS costing).  Chapter 2 
explains the methodology, data sources and results of the exercise in measuring 
proportionality.  Results indicate that the majority of countries in the dataset ‗overspend‘ on 
HIV/AIDS relative to the most commonly employed measure of disease burden, the DALY.  
This result, however, belies the fact that ‗underspending‘ is far more egregious than 
overspending – while most countries ‗overspend‘, the total amount in surplus of 
proportionality in overspending countries is dwarfed by the total amount still needed to reach 
proportionality in underspending countries.  Total global HIV/AIDS resources are still 
grossly inadequate to bring all countries‘ spending on the disease in line with their respective 
disease burdens.  Interestingly, South Africa is the country that needs to increase its absolute 
AIDS spending the most in order to spend proportionately.    
 
Chapter 3 interrogates the structure and assumptions of the AIDSCost model and compares 
its outputs with those of ASSA2003, South Africa‘s foremost epidemiological model of the 
HIV/AIDS virus.  Since ASSA2003 utilises a large amount of country-specific data, and 















    
benchmark.  Results indicate that AIDSCost is based on various troubling assumptions that 
lead to serious problems of overestimation.  AIDSCost produces cost estimates for South 
Africa that are approximately double those that correspond to ASSA2003‘s epidemiological 
outputs.  To the extent that AIDSCost‘s country-specific outputs are a proxy for its overall 
quality, this suggests that the model is deeply flawed.  Accordingly, it is argued that the 
model should be significantly overhauled before it is used by anyone to argue anything.   
Further, it is argued that one of the model‘s co-creators, in employing AIDSCost, uses 
unreliable estimates as a basis for arguing for a shift in donor focus from AIDS treatment to 
prevention.  Chapter 4 concludes.   
 
It is not the intention of this paper to answer the question of whether the world spends too 
much on AIDS.  Rather, it seeks to contribute a measure of clarity to the debate on whether a 
‗disproportionate‘ amount is being spent on the disease.  To spend ‗disproportionately‘ on 
AIDS is not necessarily to be in error.  In many cases it is appropriate to allocate spending in 
line with the marginal benefits of additional funding, and this may result in seemingly 
disproportionate allocations.  However, as we shall see, measures of proportionality can 
provide a useful first step in deciding how to allocate what limited resources are available for 
health.  This is especially so because data available for marginal cost effectiveness 
calculations at the global level are severely limited.  Similarly, critiquing AIDSCost does not 
tell us how much more money AIDS will require in the years to come, but it does allow us to 
place ‗danger, unstable ground‘ signs on at least one path available to those interested in the 
future costs of the disease.  At bottom, both exercises are driven by the recognition that, 
however precise they at first appear to be, all numbers need to be interrogated before they can 

























    
Chapter 1 - Literature review and the need for 
further research 
 
1.1 - Proportionality 
 
Interest in proportionality has been driven by the need to sensibly allocate extremely scarce 
global healthcare resources.  Scarcities in global health spending have and do force health 
initiatives into competition with one another (Reich, 1995; Segall, 2003; Waddington, 2004; 
MacKellar, 2005; as quoted in Shiffman, 2006).  The need to prioritise, thus, cannot be 
ignored.  AIDS kills, but so do many other diseases.  AIDS needs more money, but perhaps 
diarrhea needs it more.  It would of course be most helpful if each additional dollar of 
healthcare could be allocated in such a way as to maximise its impact on disease burden.  As 
Bongaarts and Over state in their contribution to the aforem ntioned Science debate: 
 
―regardless of data discrepancies, we believe that health spending should not be 
allocated in any strict proportion to disease burden, but rather in proportion to the 
marginal return in terms of reducing disease burden. We advocate allocating 
incremental resources to the interventions that save the most life-years per dollar 
spent‖ (2010: 176). 
 
Unfortunately, such maxim sation of marginal benefit is – currently, at least – very difficult 
to do, if not impossible.  As we shall see, it is difficult to obtain accurate data on even 
aggregate allocations of healthcare resources.  Calculating which interventions ‗save the most 
life-years per dollar spent‘ requires a level of precision and coverage that is currently 
unavailable in the global data bank.   
 
In the absence of certainty regarding where each dollar will have the most impact, scholars 
have been forced to consider a broader measure for which data are available – namely, the 
proportionality between that share of healthcare funding allocated to a specific disease and its 
share of the disease burden.  Chapter 2 expands on specific measures of disease burden, but it 
is important to note here that all measures aim to quantify the harm to human life that a given 















    
suggests that the most dangerous conditions should receive the most attention.  As early as 
1999, the Institute of Medicine in the United States, in order to allocate scarce funding 
resources, ―proposed that the amount of disease-specific research funding provided by the 
National Institutes of Health be systematically and consistently compared with the burden of 
disease for society‖ (Gross et al, 1999: 1881).  More recently and more relevantly, UNAIDS 
has accepted a measure of proportionality.  Its recently created Domestic Investment Priority 
Index indicates what levels of country spending ―might be expected given their disease 
burden and government resources‖ (UNAIDS, 2010a: 147).  It is important to reiterate that 
proportionality does not tell us precisely how healthcare resources should be allocated.  This 
is not least because measures of disease burden (as we shall see) depend on specific 
assumptions and cannot capture the true complexity of disease.  Proportionality does, 
however, give us some idea of whether the most harmful conditions are being placed high on 
the funding agenda.  In so doing, it provides a useful foundation for debate.    
 
The question of whether AIDS spending is disproportionate to its disease burden is a 
relatively recent one.  Still, important contributions have been made.  MacKeller (2005) 
investigates aggregate official development assistance by all OECD donors to all countries 
for the years 1993 and 2003, and finds that AIDS received far greater donor attention than 
any other condition.  In particular, she notes that it received more funding per DALY than all 
other infectious diseases, maternal and perinatal conditions and nutritional deficiencies.  
Shiffman (2006) examines funding for 20 communicable diseases that heavily affect 
developing countries from 42 major donors.  He finds that AIDS is prioritized relative to 
other diseases, receiving 46% of donor funding in the period 1996-2003 but representing only 
31% of developing country disease burden.  England (2007) claims that AIDS constitutes 5% 
of the disease burden in low and middle income countries – ―less than...respiratory infections, 
perinatal conditions, or ischaemic heart disease‖ (2007: 344) - but, in 2004, received 21% of 
international health aid.  He does not, however, explain how he arrived at these figures.   
 
Shiffman (2008) explicitly tackles the question of whether donor commitments to AIDS have 
displaced spending on other diseases.  He finds that, during the period 1992 to 2005, both the 
level of aid directed towards AIDS and its increasing share in total health aid budgets implied 
a high prioritization of the disease relative to other conditions.  He notes that ―overall, the 
evidence indicates that displacement is likely occurring, but that aggregate increases in global 















    
(2009) conduct a detailed analysis of trends in international health aid between 1990 and 
2007, and note that development assistance for AIDS has seen significantly greater increases 
than that for other conditions, and also that it receives the most aid per DALY.  Moran et al 
(2009) examine key data from the first of five annual surveys - commissioned by the Bill and 
Melinda Gates Foundation – of global Research and Development investments into 
developing country diseases, their analysis aimed at ascertaining just which diseases qualify 
as ‗neglected‘ in terms of funding.  They find that in 2007 Tuberculosis, Malaria and AIDS 
received a significantly greater share of funding – with AIDS receiving the most out of these 
– than many other conditions with high disease burdens.  They state that:  
 
―The predominance of research into new products for HIV/AIDS, malaria, and TB is 
understandable—and the generosity of funding in these areas is a credit to donors—
however, other high-burden, high-mortality diseases remain badly under-funded: 
pneumonia and the diarrhoeal illnesses stand out in this regard...For instance, HIV, 
TB, and malaria accounted for 125 million DALYs in low- and middle-income 
countries in 2004 and received nearly 80% of total funding; while pneumonia and 
the diarrheal illnesses accounted for 165 million DALYs in the same year but 
received less than 6% of total funding‖ (Moran et al, 2009: 0145). 
 
The above studies seem to indicate donor bias towards AIDS at the expense of other diseases, 
but suffer from important shortcomings.  Firstly, where it is asserted that AIDS receives more 
per DALY than other diseases (proportionality implies equal funding per DALY), little 
information is given on where disproportionate spending is occurring.  Aggregate statistics 
are interesting, but the a alysis of trends misses country-specific results that may well be 
important to policymakers.  If disproportionate spending is occurring, where is it occurring?  
How much spending must be redistributed from AIDS to other conditions in Ghana, say, for 
proportionality to be satisfied?  Further, are there particular countries that are driving the 
trend?  Is spending below proportionality (henceforth, ‗underspending‘) the norm for most 
countries, with cases of spending above proportionality (henceforth, ‗overspending‘) 
representing only powerful outliers?  Secondly, the studies reviewed above, through no fault 
of their own, contain data only up until 2007.  If one recalls that international aid for AIDS 
jumped from $4.9 billion to $7.7 billion between 2007 and 2008 – a near 60% increase – it is 















    
2007 (such as those drawn by Nattrass and Gonsalves, 2010), even if given at the country 
level, are largely obsolete.  
 
Thirdly, and even if these first two issues were solved, the studies above – with the exception 
of Moran et al‘s - focus merely on donor assistance.  There is no reason why donor assistance 
would – or should - follow DALYs in any given country.  This is not because donor priorities 
may run counter to developing country need – Shiffman (2006: 412), for example, notes that 
issues such as national security and various other political factors may play a role in a 
‗provider interest‘ understanding of donor aid.  Rather, it is because a proper understanding 
of proportionality within any given country, given developing country needs, implies 
inclusion of domestic government spending as well as international aid.  If certain diseases 
are heavily prioritized by developing country governments at the expense of others, donor 
spending that follows disease burden will skew overall spending in favour of such diseases.  
Few meaningful conclusions, thus, can be made on the basis of donor spending alone. 
 
The first and third concerns have been partially addressed by two very recent studies.  
Nattrass and Gonsalves (2010) use 2006 and 2007 UNAIDS and World Health Organization 
(WHO) National Health Accounts (NHA) data to compare country-level spending on AIDS – 
including domestic expenditure and international aid – as a proportion of overall health 
spending to the proportion of overall DALYs attributable to AIDS.  Their results, shown in 
Figure 1.1, indicate a trend towards under-spending, and provide some country-level detail on 


























    




 Source: Nattrass and Gonsalves, 2010: 175 
   
Amico et al (2010), meanwhile, also use UNAIDS and WHO data to conduct the same, 
though more systematically explained, exercise for 2007.  They include 65 countries and, in 
addition to the proportionality exercise, analyse AIDS spending per capita, total AIDS 
spending and the statistical correlation between AIDS spending and HIV prevalence.  Of 
primary relevance is their finding that Sub-Saharan Africa (SSA) is the only region where the 
share of AIDS spending exceeds the share of DALYs attributable to the disease.  They state 
that ―on the whole, most countries are spending rational amounts based on the impacts of 
HIV‖ and note that only a few select countries in SSA account for the region‘s overspending 
result (2010: 7). 
 
There are still questions left unanswered by these contributions, however, and not just those 
that pertain to the potential differences between 2007 and 2008.  Nattrass and Gonsalves use 
2006 spending data for some countries and 2007 data for others, which makes things a little 
confusing.  A static picture such as theirs (Figure 1.1), which plots one entry per country on 















    
at a given point in time.  But this is not the case.  Further, the WHO data on total health 
expenditure that they use includes private expenditure.  The UNAIDS data on AIDS spending 
they use, however, does not include private expenditure (UNAIDS and WHO, 2009a).  This 
is likely to bias their vertical axis indicator (proportion of overall health expenditure spent on 
AIDS) downward or, in other words, underestimate the true proportion of total health funds 
spent on AIDS.  This downward bias is likely to be more severe in middle income and rich 
countries because of higher levels of out of pocket expenditure.  Amico et al, meanwhile, do 
not include data on South Africa – the country with the largest population of HIV positive 
people – in their study.  Since they report results by region, this severely skews their findings 
for Sub-Saharan Africa.  Further, they do not provide results on spending relative to DALYs 
that are disaggregated by country (though they do this for AIDS spending per capita, 
prevalence and other indicators).   
 
Finally, and most significantly, Bongaarts and Over (2010: 177) – in direct reply to the 
Nattrass and Gonsalves exercise - raise an intriguing concern over the source of AIDS 
spending data.  They contend that UNAIDS data underestimates AIDS spending by excluding 
a large portion of international AIDS assistance.  They note large discrepancies between 
UNAIDS and OECD data for countries such as Botswana, Namibia, Senegal, South Africa 
and Nigeria.  OECD data, they claim, provide more reliable estimates in this regard: 
 
―A key reason for this discrepancy is that a large part of foreign donor expenditures 
passes directly through contractors to AIDS patients without ever being reported to 
the government. If the donor-reported OECD data rather than the recipient-reported 
U.N. data are used, AIDS‘s share of total health spending is larger than AIDS‘s 
share of the disease burden in more countries than Nattrass et al.‘s figure [Figure 
1.1] suggests‖ (2010: 177). 
 
It is true that the two data sources approach data collection from different angles.  The 
OECD‘s Creditor Reporting System (CRS) contains data disaggregated according to two 
‗channels of delivery‘: NGOs and Civil Society and Public Sector (OECD, 2010a).  An 
inspection of the recently declassified reporting directives for the OECD‘s Development 
Assistance Committee (DAC) confirms that each channel of delivery is ―normally linked to 















    
directly accountable to it‖ (OECD, 2010b: 8).  In other words, some funds are channelled 
directly to NGOs and other organisations without passing through government.   
 
The National AIDS Spending Assessment exercises, from whence UNAIDS sources its 
spending data, do attempt to capture such funds (UNAIDS and WHO, 2009a).  However, 
their data collection teams are organised by country governments.  Health resource tracking is 
a vast and complex challenge.  Indeed, agencies such as the WHO, UN and OECD have yet 
to properly align their systems of accounting for health expenditure (see Powell-Jackson and 
Mills, 2007).  Given this complexity, it is inevitable that some funding will be missed as 
teams attempt to solicit information from the many agencies operating within their countries 
(the specifics of these various funding flows are explored more thoroughly in Chapter 2).  
CRS data may well provide a better picture of international assistance for AIDS – at least for 
the OECD member countries. 
 
Considering the above, and taking into account the funding controversies unfolding even as 
this is written down, there are several pressing needs that need to be addressed.  Firstly, 
regardless of methodological or data questions, the latest data need to be interrogated.  It 
seems probable that anyone wishing to use existing evidence to argue, one way or the other, 
would like to avoid the retort: ‗we don‘t believe you because it‘s just not like that anymore‘.  
Secondly, it needs to be seen whether UNAIDS and OECD data do differ significantly, and 
whether such difference significantly affects overall findings.  It is worth knowing if results 
that set a country on one side of a very contentious line are sensitive to the source of the data 
used.  Finally, it would be extremely helpful to present a detailed breakdown of which 
countries spend disproportionately and by how much.     
 
1.2 - Modelling the future costs of AIDS interventions 
 
There exist relatively few models that researchers can use to estimate the future global costs 
of interventions related to the AIDS epidemic.  Spectrum, a publicly available suite of 
modeling software available through the UNAIDS website, is perhaps the most widely 
known.  It allows for projection of various types of costs – including laboratory costs, first- 
and second-line ART and nutritional supplements – associated with AIDS interventions 















    
28 million new HIV infections between 2005 and 2015 would be approximately $3900 per 
infection (2006: 1474).  Spectrum has been available since 2004 and has been updated and 
modified several times.  Kumaranayake (2008) has reviewed the available empirical and 
mathematical modeling exercises aimed at gauging the costs of AIDS interventions and their 
scaling up.  Though her summary (2008: S27) indicates that seven studies modeled the future 
(relative to their year of publication) costs of AIDS interventions, most of these are now 
outdated or involve ad hoc calculations (see Table 1.1 below).   
 
Both Gutierrez et al (2004) and Schwartlander et al (2001) project various resource 
requirements related to sets of interventions for the year 2005, Broomberg et al (1996) base 
their hypothetical prevention strategies on data available in 1996, and two of the three 
projections generated by the World Health Organisation‘s Commission on Macroeconomics 
and Health (CMH) focused on the year 2007 (Kumaranayake et al, 2001).  The third CMH 
projection is for the year 2015.  Though not yet outdated, it involves a time- and intervention-
specific projection and does not provide software that can be used in a range of different 
scenarios.  Bertozzi et al (2004) include details of their modeling methodology that allow for 
its replication, but application to other settings requires the sourcing of new data and 
substantial software programming (see Table 1.1 below).  The only other relevant paper 
mentioned by Kumaranayake is by Stover et al (2006) – which, as mentioned, made use of 
Spectrum.  More recently, Hecht et al, in ―modeling carried out for the AIDS 2031 project‖, 
estimated that if the AIDS epidemic continues on its current trajectory global resource 
requirements for the disease could triple – to $35 billion annually – by 2031 (2009: 1591).  
Their estimates cite ‗author‘s calculations‘, however, and no modeling package is referred to.  
 
It is this dearth of publically available models that McCarthy and Over (2009) sought to 
address.  Their recently developed AIDSCost model provides open source software that can 
be used to make projections on global and country- and region-specific costs of AIDS 
treatment until the year 2050.  This model shall be thoroughly discussed in Chapter 3, but it is 
important to note that Over (2008) has employed it to argue that funding AIDS treatment 
programmes will soon become untenable for the United States.  If it continues to do so, he 
argues, it will face ―reputational risk‖ (2008: 307).  Since each person already on ART will 
die if funding for his/her treatment is removed, he argues, it will reflect very badly on the US 
if it reduces its treatment programme at any time.  Thus, in order to avoid saddling itself with 















    
shift focus away from treatment and toward prevention.  More recently, Over (2011: online) 
has used the AIDSCost model to argue that recent findings (UNAIDS, 2011: online) 
confirming that ART prevents HIV transmission should not prompt a greater focus on 
treatment.  ―Modelling shows‖, he states, that even given this treatment-as-prevention 
finding, treatment costs will still become untenable and therefore ―behavioural HIV 
prevention still deserves the highest priority‖ (Over, 2011: online).        
 
McCarthy and Over (2009: 29) have solicited critique of their model, as well as its 
comparison with other modeling packages.  Further, the model is being used to support strong 
positions regarding AIDS treatment at a time when funding for it is very much under threat.  
The controversy that unfolds in the comments following Over‘s article (2011: online) confirm 
its relevance to pressing issues.  Finally, its ease of use, geographical versatility (it covers 
over 100 countries) and public availability mean that it has the potential to be used by many 
who may have real influence over public health policy.  For these reasons, it is imperative 
that the reliability of AIDSCost be tested before it is used to leverage further positions or 
support decision-making.  While it would be ideal to test all available models, including 
Spectrum, for their reliability, gauging the quality of even a single model (as we shall see in 
Chapter 3) is a considerably involved exercise. 
 
 
         


























    
Table 1.1: Summary of literature 
Table 1.1 - S umm ary of li terature  
Empirical findings on proportionality 
Author(s)(year)[period analysed] Methodology Main findings 
 
MacKellar (2005)[1993 and 2003] 
Shiffman (2006)[1996-2003]  
England (2007)[2004] 
Shiffman (2008)[1992-2005]  
Ravishankar et al (2009)[1990-2007] 
Moran et al (2009)[2007] 
 
Compare official 
development assistance for 
AIDS to assistance for other 
diseases heavily affecting 
low and middle income 
countries. 
 
AIDS receives significantly 
more donor funding than other 
high burden diseases, 
including per DALY. 
 
Nattrass & Gonsalves (2010)[2007] 
Amico et al (2010)[2007] 
 
Compare proportion of total 
health expenditure (WHO 
data) allotted to AIDS 
spending (UNAIDS data) to 
proportion of total DALYs 
accounted for by the disease 
(WHO data for 2004) 
 
Though some countries’ AIDS 
spending is above the level of 
proportionality, there is a 
general trend towards 
spending that is below this 
level.  Amico et al find that 
Sub-Saharan Africa is the only 
region that ‘overspends’. 
 
Bongaarts and Over (2010)[2007] 
 




There is a discrepancy 
between UNAIDS and OECD 
estimates of AIDS spending for 
some countries 
Modelling the future costs of AIDS 
Author(s)(year)[projection period] Ad hoc / Can be used again for future projections 
 
Broomberg et al (1996)[undefined] 
 
Outlines method of calculating costs related to hypothetical 
programme design of a number of HIV prevention strategies.    
 
Gutierrez et al (2004)[2005] 
 
Once-off series of projections that attempt to gauge the costs 
of the WHO and UNAIDS ‘3X5’ initiative (3 million people on 
ART by end 2005) 
 
Kumaranayake et al (2001)[2007, 2015] 
 
Once-off WHO Commission on Macroeconomics and Health 
projections.  One 2007 projection focused on the costs of 
expanding lower levels of health systems such as outreach 
services and health posts.  The other 2007 and 2015 projection 
focused on scaling up priority programmes with investments 















    
 
Schwartlander et al (2001)[2005] 
 
Once-off projections for 2005 of AIDS resource needs 
(prevention and care) in 135 low and middle income countries. 
 
Bertozzi et al (2004)[2007] 
 
Outlines methodology to allow for replication, but provides no 
software or data.  Presents results of model projections for 
2007 concerning scale-up of AIDS interventions (palliative 
care, diagnostic HIV testing, treatment of and prophylaxis for 
the prevention of opportunistic HIV infections, ART lab work 
and monitoring) in low and middle income countries.  
 
Hecht e al (2009)[2031] 
 
Once-off projections regarding AIDS resource requirements up 
until 2031 over a range of different prevention and treatment 
scenarios  
 
McCarthy and Over (2009)[until 2050]  
 
AIDSCost comes in the form of open-source software that can 
be used by anyone with the statistical program Stata.  It allows 
for the projection of future global costs of ART as well as for 




The Spectrum suite of software is able to accommodate both 
multi-country and country-specific projections regarding the 



























    
Chapter 2 - Proportionality 
 
This chapter proceeds as follows.  Section 2.1 discusses data sources and choice of indicators.  
Section 2.2 summarises results.  Section 2.3 discusses weaknesses in the analysis.  Section 5 
concludes.   
 
2.1 - Indicators and Data Sources 
 
Calculating proportionality, on the face of it, is not at all complicated.  It merely involves the 
comparison of two ratios: (1) that proportion of the health budget spent on AIDS and (2) that 
proportion of total disease burden that is attributable to AIDS.  Thus, the proportionality 
condition is satisfied if: 
 
                
                    
  
                   
                    
 
 
Properly defining and measuring each indicator, however, is a complex ordeal involving 
multiple data sources and variables.  Accordingly, the indicators used in this chapter‘s 
proportionality exercise will be explained in some detail.  As the issues discussed are 
contentious, the greatest care has been taken to ensure minimal experimentation with the 
data.  Further, care has been taken to ensure that the selected measures have been both widely 
and officially used.  The approach is deliberately non-technical and can be followed by 
anyone with the necessary time and inclination to do so.    
 
Disease burden – AIDS DALYs and Total DALYs 
 
The Disability Adjusted Life Year (DALY) attempts to provide a single measure quantifying 
the mortality and morbidity associated with disease and various forms of injury.  It improves 
upon simpler measures of disease burden, such as deaths attributable to a given condition, by 















    
to any properly considered conception of true affliction.  A simple summation of the indicator 
is given thus: 
 
―The disability-adjusted life year (DALY) extends the concept of potential years of 
life lost due to premature death to include equivalent years of ―healthy‖ life lost by 
virtue of being in states of poor health or disability. One DALY can be thought of as 
one lost year of ―healthy‖ life, and the burden of disease can be thought of as a 
measurement of the gap between current health status and an ideal situation where 
everyone lives into old age, free of disease and disability‖ (WHO, 2008a: 3). 
 
The unweighted indicator comprises two measures: years of life lost due to premature death 
(YLL) and years of life lost due to disability (YLD).  YLL for a particular condition 
considers the number of deaths at a given age and for a particular sex, multiplied by a global 
standard life expectancy (in number of years still to be lived) at that age and sex (WHO, 
2011a: online).  YLL is measured relative to the same ‗ideal‘ standard life expectancy for all 
countries – 80 years at birth for men and 82.5 for women, as in the original 1990 DALY 
calculations (AbouZahr and Vaughan, 2000: 78).  YLD, meanwhile, is calculated with 
reference to the ‗disease weight‘ or relative severity of disease as measured on a scale 
between 0 and 1 (0 being perfectly healthy and 1 being dead).  It can be calculated as the 
number of incidences of the disease multiplied by the disease weight and the average duration 
of disease from contraction to either remission or death (WHO, 2011a: online).  Disease 
weight is the same for all countries, but varies according to age with regard to some 
conditions (see below) (WHO, 2008b).   
 
‗Social preferences‘ are applied to the simple calculus described above in two steps.  First, 
future DALYs are discounted relative to present ones, which is meant to factor in the societal 
preference for disease alleviation today over disease alleviation tomorrow.  Second, non-
uniform age weights are applied so that years of life lost carry less weight in the elderly and 
the very young.  This reflects an assumption of ‗welfare interdependence‘, where those in 
infancy and old age are supported by others while those in adulthood support others 
(Robberstad, 2005: 186).  In particular, and including both discounting and age weighting, an 
infant‘s death incurs a cost of 33 DALYs while the death of a person aged 5-20 incurs a cost 
















    
 
―DALYs are the sum of the present value of future years of lifetime lost through 
premature mortality, and the present value of years of future life-time adjusted for 
the average severity (frequency and intensity) of any mental or physical disability 
caused by disease or injury‖ (Fox-Rushby and Hanson, 2001: 326).      
  
DALYs (for 1990) were first introduced in the 1993 World Development Report, while 
updates were conducted for the years 2002 (in 2005) and 2004 (in 2008).  A further update is 
currently underway (WHO, 2011a: online).  The update conducted in 2008 for the year 2004 
shall henceforth be referred to as ‗the 2004 update‘.  The proportionality exercise in this 
paper uses the latest data available from the WHO, which are sourced mainly from the 2004 
update but also include additional updates – also for the year 2004 - following consultation 
with WHO member states in late 2008 (WHO, 2009).  The 2004 update uses non-uniform age 
weights as described above and a discount rate of 3% per annum (WHO, 2008a).  Disease 
weights for HIV cases (0.135) vary according to age and are sourced from the original 1990 
calculations.  Those for AIDS cases not on ART (0.505) are uniform across age groups and, 
again, are identical to those in 1990.  Disease weights for AIDS cases on ART (0.167) were 
revised in the 2004 update, though they too are uniform across age groups (WHO, 2008b: 2).  
‗Total DALYs‘ in a given country include all DALYs for all diseases, conditions and injuries.  
‗AIDS DALYs‘ include those DALYs attributable to AIDS, which are identified by the 
Global Burden of Disease code W009 in the WHO dataset (WHO, 2009).   
 
It is important to note that there are other measures of disease burden, among them Quality 
Adjusted Life Years (QALYs), Life Years gained and Health Adjusted Life Expectancy.  
Their histories and methodological idiosyncrasies are summarized elsewhere (see, for 
example, Sassi, 2006; Robberstad, 2005; and Gold et al, 2002.)  Further, some have raised 
objections, many of them ethical, about the way that DALYs are calculated and used (see 
Anand and Hanson, 1997, particularly with regard to the ethics of age weighting; as well as 
Arnesen and Nord, 1999; AbouZahr and Vaughan, 2000; and Gold et al, 2002).  The DALY, 
like any metric, is an imperfect tool that does not capture the entire realm of disease.  It is, 
however, widely used by the international community in general and by the WHO in 
particular.  Further, by including consideration of morbidity, it provides a more complete 
picture of the harm caused by disease than measures (such as Life Years Gained) that 















    
transparent than those used in the calculation of QALYs, which also include consideration of 
morbidity (Murray, 2004: 430).  Finally, as we have seen, DALYs remain the standard 
measure of disease burden used by those seeking to measure AIDS proportionality. 
 
Total Health Spending 
 
The measure of total health spending employed here attempts to include all spending on 
health by the public sector and the international community.  As in Amico et al (2010), 
private sector spending on health - as given by out of pocket expenditure and private health 
insurance – is excluded.  This is done for two reasons.  Firstly, neither UNAIDS nor OECD 
data on AIDS spending includes private expenditure.  Including it in the denominator and not 
the numerator would thus skew the calculations.  Secondly, even if private AIDS expenditure 
data were available, including it could still arguably be inappropriate.  The idea of linking 
spending to disease burden implicitly appeals to the need to care for the public good (or 
reduce the public ‗bad‘, one could say).  Both international aid and government spending, at 
least ostensibly, also include consideration of this public good.  There are philosophical 
grounds, then, to make a case for the redirection of government and aid resources in order to 
better serve the needy.  Such grounds are harder to establish with regard to the private sphere.  
To say that all health expenditure, including private health expenditure, should be linked to 
burden of disease is akin to suggesting a global redistribution of private resources according 
to non-private preferences.  This is both infeasible and unhelpful for current policy dialogue.    
 
Data for total health spe ding is sourced from the WHO‘s National Health Accounts (NHA) 
database.  The NHA represents a vast international effort – which includes cooperation 
between and assistance from the WHO, World Bank, the United States Agency for 
International Development and the OECD – to track the entire system of health expenditure 
within each country and ―trace how much is being spent, where it is being spent, what it is 
being spent on and for whom‖ (WHO, 2003: XIII).  The NHA methodology represents the 
current international standard for health resource tracking (Powell-Jackson and Mills, 2007: 
353).  The most recent data available are used, which include final estimates for the year 
2008.  There is, as yet, no unified database containing total health expenditure in absolute 
terms by country for the year 2008.  A new database was thus constructed by the author from 















    
and private sectors.  The country reports (WHO, 2011b) present figures in Local Currency 
Units (LCUs), but provide an indicator of average LCU per US Dollar for each year.  The 
author divided nominal LCU amounts by the LCU per US dollar figure to produce health 
expenditure figures for each country in 2008 US Dollars.    
 
Expenditures in each country report are separated according to ‗financing agent‘.  Public 
expenditure agents include general government, the ministry of health and social security 
funds.  Private health expenditure agents include out of pocket expenditure, private health 
insurance and non-profit institutions serving households.  A careful reading of the NHA 
Guide to Producing National Health Accounts (WHO, 2003) indicates that funds are 
classified according to direct health spending by the financing agent regardless of financing 
source.  In other words, general government health expenditure in the NHA includes not only 
domestic funds, but also funds received from international donors and spent by the 
government.  Similarly, expenditure by non-profit institutions includes funding received from 
private sources (philanthropic foundations or businesses, for example), government agencies 
and international sources.  The NHA guide provides an example of a survey soliciting 
spending information from an NGO which illustrates this (WHO, 2003: 136).   
 
This creates a problem.  A portion of both donor and government funding, which should be 
included in the chosen measure of total health spending, flows to non-profits.  However, so 
too does some private funding.  Since funding is presented according to financing agent and 
not financing source, there is no way to separate that part of non-profit expenditure financed 
by the private sector and that part financed by the public and international sectors.  Though 
the country reports do include information on total funding from international sources, there 
is no indication of the relative shares going to each of the funding agents.  There is thus no 
choice but to include non-profit institutions serving households for the purposes of this study.  
While this forces the inclusion of some invisible amount of private health expenditure – 
which biases the share of AIDS spending in total health spending downwards, as explained in 
Chapter 1 with reference to Nattrass and Gonsalves (2010) – excluding the non-profit sector 
produces total health expenditure figures for many countries that are smaller than total AIDS 
spending figures (discussed next).  This is clearly impossible.  It would seem that private 
expenditure represents a small portion of non-profit funding relative to combined government 
and international financing.  Excluding the non-profit sector would pose a different but bigger 















    
by Amico et al (2010), though they did not discuss it or consider the implications of including 
the non-profit sector for their analysis.   
 
Spending on AIDS 
 
AIDS spending data is provided from three alternative data sources in this study: UNAIDS, 




The National AIDS Spending Assessment (NASA), created by UNAIDS, represents ―the 
most ambitious attempt to collect [AIDS] spending information at the national level and to 
monitor expenditures at the global level‖ (Amico et al, 2010: 2).  The NASA framework 
attempts to account for all AIDS funding flows from all sources and to all projects in a given 
country.  This includes both health and non-health related AIDS activities, such as social and 
prevention campaigns.  One could say that it is to AIDS expenditure what the NHA is to 
health expenditure.  Important overlaps exist between the NHA and NASA frameworks.  
Indeed, UNAIDS (together with the United States Agency for International Development and 
the WHO) has developed a comprehensive guide on linking the NHA implementation efforts 
with those of NASA:   
 
―While their [NASA‘s and NHA‘s] objectives are not identical, they have 
overlapping components and so NASA and NHA implementation can occur in a 
coordinated manner to avoid duplicative and redundant resource-tracking efforts. By 
doing so, the frameworks can meet the needs of both HIV/AIDS and general health 
care stakeholders, national and international‖ (UNAIDS and WHO, 2009a: XI).   
 
These overlaps, which include adherence to similar norms of accounting and health resource 
tracking, make for a smooth pairing of NASA data with the NHA data on total health 
expenditure described above.  As mentioned, NASA data do not include private expenditures 
on AIDS.  As with the NHA data, NASA data (henceforth UNAIDS data) are for the year 
2008 in 2008 US Dollars.  All data, except for that on South Africa, were sourced from the 
AIDSinfo database for the purposes of this study (UNAIDS, 2010b).  Data for South Africa 















    
(UNGASS) country report (Republic of South Africa, 2010).  It is unclear why this data was 
not included in the AIDSinfo database.  Data for each country includes spending from both 




The OECD Creditor Reporting System contains official data from the 23 member countries of 
the Development Assistance Committee on commitments and disbursements of international 























 United Kingdom 
 United States 
 (EU institutions) 
 
International development assistance is defined thus: 
 
―those flows to countries and territories on the DAC List of ODA Recipients and to 
multilateral development institutions which are: 
i.  provided by official agencies, including state and local governments, or by their 
executive agencies; and 
ii.  each transaction of which: a)  is administered with the promotion of the economic 
development and welfare of developing countries as its main objective; and b)  is 
concessional in character and conveys a grant element of at least 25 per cent 
(calculated at a rate of discount of 10 per cent)‖ (OECD, 2011b: online) 
 
A commitment is a ―firm written obligation by a government or official agency, backed by the 
appropriation or availability of the necessary funds, to provide resources of a specified 
amount under specified financial terms and conditions and for specified purposes for the 
benefit of the recipient country‖.  A disbursement, meanwhile, is ―the placement of resources 
at the disposal of a recipient country or agency, or in the case of internal development-related 
expenditures, the outlay of funds by the official sector‖ (OECD, 2010b: 8).  
 
The CRS includes both bilateral assistance flowing from DAC members to recipient countries 















    
the Global Fund.  Donors self-report to the DAC and are guided by a set of detailed reporting 
directives that define how funding is to be classified and presented (Powell-Jackson and 
Mills, 2007: 357).  The NHA framework builds upon the standards for health accounting set 
forth by the OECD (WHO, 2003: XIV) and, as a result, CRS data pair well with the chosen 
measures of total health expenditure.  CRS data group projects funded under ‗purpose codes‘, 
which reflect the main purpose for which funds are used.  Two purpose codes pertain to 
spending on AIDS: ‗STD [Sexually Transmitted Disease] control including HIV/AIDS‘ 
(13040) and ‗Social mitigation of HIV/AIDS‘ (16040).  Together, these two purpose codes 
attempt to capture all funds from the world‘s main donors, both health and non-health, 
directed towards the fight against AIDS.  Data are grouped by recipient country, recipient 
region and donor country and agency.  Data do not include funding from private donors such 
as the Bill and Melinda Gates foundation, and only consider public expenditure on ODA 
channelled through DAC member country governments.       
 
For the purposes of this study, 2008 disbursement data for ‗STD  control including 
HIV/AIDS‘ and ‗Social mitigation of HIV/AIDS‘ from all donors for the year 2008, measured 
in 2008 US Dollars (OECD, 2010a), were combined.  This delivered a single international 
AIDS funding figure for each recipient country which can be thought of as a kind of CRS 
version of the UNAIDS data indicator ‗domestic spending on HIV from international 
sources‘.  UNAIDS also provides data for AIDS spending from domestic sources alone – 
‗domestic HIV spending from public sources‘.  UNAIDS data on AIDS expenditure from 
public (or domestic) sources were combined with CRS data for expenditure from 
international sources.  This produced the OECD estimate of AIDS spending used in this 
study.  This combination should not be controversial.  There is no double counting, as the 
UNAIDS data differentiates clearly between public and international financing.  Further, the 
CRS contains no data on expenditure from domestic sources.  Lastly, as has already been 
explained, it is important to consider AIDS expenditure in each country from both domestic 
and international sources if a meaningful contribution to the literature is to be made.           
 
Just how much do UNAIDS and OECD data differ? 
 
As a prelude to the main investigation, it is useful to interrogate the question of whether 















    
sources on AIDS spending from international sources were available for 87 countries 
(Appendix 1.1).  Comparing the data yields interesting results: 
 





Figure 2.2:  2008 Absolute deviation of OECD from UNAIDS data, AIDS spending from 
























































































    
 
Figure 2.3:  2008 Percentage deviation of OECD from UNAIDS data, AIDS 
spending from international sources 
 
 
*Line break is owing to a 0 international spending value for Grenada in UNAIDS data 
 
One can see from Figure 2.1 and 2.2 that the OECD and UNAIDS data generally follow each 
other quite well.  Indeed, their figures for total AIDS spending from international sources are 
very similar: $3.281 billion in OECD and $3.251 in UNAIDS.  Figure 2.2, however, 
demonstrates that this similarity belies some extreme inter-country discrepancies.  It shows 
that OECD data routinely deviate by over 100% from UNAIDS data, with figures for Angola 
showing a discrepancy of 316%.  The data disagree most on Sao Tome and Principe, with a 
remarkable deviation of 1290% for this country ($700 000 in OECD and $50 000 in 
UNAIDS).  For the sake of readability, the wayward island was removed from the deviations 
graph.  Importantly, deviations show no regular pattern, implying that there is no routine 
under- or over-estimation of one data source vis a vis the other.  Recall for a moment the 
aforementioned debate in Science involving Nattrass and Gonsalves (2010) and Bongaarts and 
Over (2010).  It is clear from the above that Bongaarts and Over (2010: 177) use only 
selective evidence when they imply that UNAIDS data are likely to underestimate the number 
of countries overspending on AIDS relative to its disease burden.  The data sources do 
























































    
AIDDATA 
 
Though it is not central to the data issue brought up by Bongaarts and Over (2010), it is 
prudent to include yet another source of AIDS spending to clear up some questions left 
unanswered by CRS data.  Firstly, it is troubling that the most encompassing measure of 
AIDS spending in the CRS seems to include other forms of STD control than those directed 
towards AIDS (‗STD Control including HIV/AIDS‘).  If a large number of STD spending 
unrelated to AIDS is being included, this will naturally bias AIDS spending figures upwards.  
Secondly, it would be useful to get an idea of how many projects classed under different 
purpose codes include AIDS components.  This would provide a more complete picture of 
true AIDS spending.  Thirdly, it would be useful to include funding from non-DAC donors 
not included in the CRS as well as funding not classified as Official Development Assistance.  
To investigate these issues, alternative data were sourced for the purposes of this study from a 
development finance portal named AidData. 
 
AidData, formed in 2009, is the result of a collaboration between, firstly, the Project-Level 
Aid Database (PLAID) team at the College of William and Mary and Brigham Young 
University and, secondly, the aid information technology provider Development Gateway.  It 
aims to provide comprehensive, project-by-project, easily-accessible data encompassing the 
entire universe of development aid.  Building on a range of official sources from a range of 
multilateral and bilateral aid agencies - including the CRS, donor agency annual reports and 
project documents – it seeks to provide rigorous and transparent data that can be used for the 
effective management of development flows.  Its data collection efforts are ambitious:   
 
―The core of the AidData project, the PLAID database, currently encompasses 
multilateral and bilateral donor activities spanning the years 1945-2009. It contains 
information from traditional aid sources such as the OECD's Creditor Reporting 
System (CRS) as well as donors not captured by the CRS and activities that do not 
fit the OECD definition of Official Development Assistance (ODA). In cooperation 
with the OECD CRS, PLAID augments existing data by publishing more complete 
project descriptions and more detailed aid project purpose codes. In particular, 
PLAID is dedicated to collecting project-level data from all multilateral donors and 
non-DAC bilateral donors (NDBs) to provide a more complete picture of 















    
AidData only replaces CRS data on those projects for which more complete information is 
available – for example, from individual project reports.  Further, it does not include private 
sector aid (AidData, 2011: online).  Its database, thus, should include all and only donor-
reported aid of the form that is required for the chosen exercise.  
 
A key strength of the database is that it provides searchable project-level data that allows for 
the extraction of projects related to a specific purpose, donor, year or recipient country.  
Detail about project aims and scope is primarily contained within project titles, short project 
descriptions (which briefly outline the aim of the project) and long project descriptions (which 
provide more detailed accounts of project components).  The most current AidData research 
release (1.9.2), which was released on the 15
th
 of April 2010 (Findley et al, 2010b), was used.  
The dataset used in this study was built thus: 
 
1.) All projects for the year 2008 that contain either of the words ‗HIV‘ and ‗AIDS‘ in their 
short descriptions, long descriptions or titles were extracted.  Since not all projects are 
described in English, projects whose descriptions include either ‗VIH‘ or ‗SIDA‘ – the 
French, Spanish, Portuguese and Italian equivalents of ‗HIV‘ and ‗AIDS‘ – were also 
extracted. 
2.) This delivered a total of 3609 projects, most of them from the CRS.  However, some CRS 
projects were missed - those that, for some reason, do not contain reference to the AIDS 
keywords in their descriptions.  In a separate exercise, thus, all records from AidData 
relating to the CRS purpose codes ‗STD control including HIV/AIDS‘ and ‗Social 
mitigation of HIV/AIDS‘ were extracted, regardless of the information contained in their 
descriptions.  Those CRS projects that were missed in the original search were then added 
to the database.     
3.) The database was searched project by project and those projects that fit the keywords but 
have no relevance to AIDS were excluded.  For example, many projects related to higher 
education contain the word ‗universidad‘, while the French for ‗aid for winter‘ is ‗aide 
d‘hiver‘.  Entries in languages other than English were translated with the help of Yahoo 
Babelfish (Yahoo, 2011: online). 
4.) Remaining projects were colour-coded in three groups.  Red projects were defined as 
those not directed towards AIDS or those that mention it only incidentally.  Many 
Tuberculosis projects, for example, mention susceptibility of AIDS sufferers to the 















    
millennium development goals or donor agency priorities.  Orange projects were defined 
as those projects that contain reference to AIDS, but only as one among several goals - 
projects aimed at HIV/TB comorbidity, for example, and those supporting microfinance 
schemes with AIDS education components.  Those programmes aimed primarily at AIDS 
were coded in white.  Commonly encountered examples of projects coded in each colour 
are presented in Appendix 1.2 to give a sense of the analytical approach adopted in this 
study. 
 
The above exercise delivered a detailed database of some 4000 projects from which to build 
information on AIDS spending.  Red projects were excluded on the basis that they had no 
clear relation to AIDS.  While many orange projects contain AIDS components, it is unclear 
what proportion of their spending is directed towards AIDS activities.  Further, including 
spending on a project split between AIDS and another disease would require inclusion of a 
portion of that other disease‘s DALYs in calculations.  Again, the proportions are unknown.  
Orange projects were thus excluded.  By far the majority of projects are for CRS records 
under ‗STD Control including AIDS‘ and ‗Social Mitigation of HIV/AIDS‘.  Interestingly, 
only four or five ‗social mitigation‘ projects, and no ‗STD control‘ projects, could be coded 
orange and none at all could be coded red – though a few hundred projects do contain 
unhelpful descriptions of the broad aims of PEPFAR that reveal very little.  Since there were 
no trends of unwarranted inclusion, the choice was made to defer to the official classification 
and to not exclude the few orange ‗social mitigation‘ projects.  Though it would have been 
very informative, a lack of descriptive specificity meant that it was not possible to ascertain 
how many projects classed under these two codes involve broader healthcare elements 
(something of direct relevance to the entire AIDS funding debate).  Interestingly, many 
projects that explicitly mention AIDS as their primary focus (coded in white) are placed under 
CRS codes such as Culture and Recreation, Health Education, Infectious Disease Control, 
Social/Welfare Services and Reproductive Health Care.  A total of 162 such projects were 
included, totalling $26.2 million. 
 
Constructing the ‗AidData‘ estimate of total AIDS funding still required several more steps.  
Since no projects related to the two AIDS-related CRS purpose codes were excluded, AIDS 
spending figures sourced directly from the CRS - as described under the previous heading – 
were used.  AidData should include these CRS entries, but the official source is preferable.  















    
then considered.  Significant discrepancies (above $100) appeared for only a handful of 
countries: Afghanistan ($1.3 million more than CRS record), Guinea-Bassau ($1.4 million 
more), Kenya ($4.7 million more) and Macedonia ($13 000 more).  These amounts were 
added to the relevant CRS country totals.  Next, the 162 additional projects identified by our 
keyword searches were summed by recipient and added to the relevant country totals.  The 
above delivered yet another estimate of total AIDS spending figures from international 
sources.  As under the previous heading, this was added to UNAIDS data on AIDS spending 




The above may appear quite convoluted.  An example may help clarify matters.  Take the 
hypothetical country Spendia.  According to UNAIDS data, Spendia spends $100 of its 
domestic health budget, largely financed by taxing its citizens (Spendians), on AIDS.  It 
spends a further $50 from international donors on AIDS.  The CRS, however, estimates that 
Spendia has received $65 in AIDS funding – not $50 – from international donors.  AidData, 
meanwhile, notes that $10 worth of projects directed at AIDS are not captured by the CRS 
(being classed in the purpose code ‗Reproductive Health‘).  Further, AidData has found better 
data for two CRS projects. Together, these projects actually cost $5 more than the CRS 
estimates.  The Spendia expenditure on AIDS is represented thus: 
 
UNAIDS =  $150 (UNAIDS domestic sources + UNAIDS international sources) 
CRS =  $165 (UNAIDS domestic sources + CRS international sources) 
AidData =  $180 (UNAIDS domestic sources + CRS international sources + extra 
donor projects not included by CRS + difference between CRS and 
AidData for some projects)  
 
The data used represent the state of the health resource tracking art.  With the exception of the 
AidData figures, all data stem from official sources and have not been subjected to any 
imputations, predictions or extrapolations.  While neither the colour-coding exercise nor the 
data provided by AidData bear the signature of the OECD, they provide an idea of the 
magnitude of funds not captured by this official source that nonetheless may be relevant to 
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Data coverage 
 
Complete DALY, total health expenditure and UNAIDS AIDS expenditure data for 2008 
were available for 118 countries.  Of these 118, adjustments (as outlined above) could be 
made with OECD international data for 87.  Of these 87, AidData adjustments could be made 
for 39.  Data on the number of people living with HIV in 2008 were available for a total of 93 
countries (UNAIDS, 2010b).  Results are presented for different data sources (see below and 
Appendix 1.3).  It was not possible to impute HIV population data for other missing countries, 
as data were also missing on their prevalence rates and for previous and later years.  High and 
low estimates for 2009 were available for the Democratic Republic of Congo, Brazil and 
China.  As no alternatives were available for these countries, the medians of these estimates 
were used (UNAIDS, 2010a).  Data on the number of people living with HIV in all regions in 
2008 were sourced from the UNAIDS 2009 Epidemic Update, and were used in order to 
calculate the percentage covered by the dataset (UNAIDS, 2009b).  As the missing data biases 
coverage of the world‘s HIV positive population downwards, the dataset includes at least the 
following levels of coverage: 
 
 76.3% globally 
 77.6% in Sub-Saharan Africa 
 71.7% in Southern Africa (including Zambia and Angola) 
 
To this author‘s knowledge, this is the most comprehensive investigation of the 
proportionality of AIDS spending to disease burden undertaken to date – Amico et al (2010), 
for example, only include 65 countries.   
 
While UNAIDS data is organised by country, a significant amount of funding in the OECD 
data is classified simply by region or as ‗bilateral aid‘ (see Appendix 1.1 for these figures).  
This has two implications.  Firstly, total regional expenditure exceeds the sum of country 
expenditure in the OECD and AidData data.  This is simply a result of adding the OECD 
expenditure for ‗Africa, South of Sahara‘, say, to that region‘s total and not to any specific 
countries.  Further, owing to the fact that some data are classified simply as ‗bilateral aid‘, 
world expenditure exceeds the sum of regional expenditure (again with OECD and AidData 















    
OECD data.  This is a simple but important way of ensuring consistency – there is no one 
answer, after all, to which countries should be included in regions such as South and Central 
Asia.   
 
A full list of countries included, labelled by region and according to data source and 
availability of HIV population data, appears in Appendix 1.1.   
 
2.2 - Results 
 
Analysis begins with aggregate statistics and moves into ever greater levels of specificity.  All 
expenditure figures represent total spending from both public and international sources.  
Where ‗overspending‘, ‗underspending‘ or the need to ‗reallocate‘ is mentioned, this only 
refers to deviations from the proportionality condition as has been defined.  Such terms as are 
used are employed for a clearer understanding of the data and do not represent conclusions 
about what individual countries should or should not do.  It is of the utmost importance the 
following is clarified: it will not be suggested, here or elsewhere, that existing AIDS funds be 
taken from any AIDS programmes.  If anything, remarks about spending above or below 
proportionality will provide a useful way to think about the allocations of future funds.    
 
World results, regional results and trends 
 
Table 2.2: Global AIDS expenditure vs. AIDS DALYs (millions 2008 US$) 
Table 2.2 - Global AIDS expenditure vs. disease burden 
    UN OECD AIDDATA 
Total 
 
10534.34 10791.64 10824.71 
AIDS spend (% of World health spend) 
 
1.16 1.35 1.36 
AIDS DALYs (% of World DALYs) 
 
3.46 
   
First, let us measure the world.  One can see that, according to all sources, the share of global 
expenditure spent on AIDS is significantly lower than its disease burden.  There is not much 


















    
Table 2.3: 2008 Regional AIDS expenditure as a percentage of total health expenditure vs. 
AIDS DALYs as a percentage of all DALYs 








WORLD   1.16 1.19 1.19 3.46 
      AFRICA 
 
11.94 12.35 12.42 10.49 
 
SUB-SAHARAN AFRICA 18.39 18.90 19.01 11.32 
 
NORTH AFRICA 0.18 0.18 0.18 0.23 
AMERICA 
 
1.11 1.13 1.13 1.57 
 
NORTH AND CENTRAL 
AMERICA 1.16 1.22 1.23 1.87 
 
SOUTH AMERICA 1.08 1.08 1.08 1.45 
ASIA 
 
0.71 0.74 0.74 1.02 
 
FAR EAST ASIA 0.67 0.68 0.68 0.99 
 
MIDDLE EAST 0.42 0.39 0.39 0.41 
 
SOUTH AND CENTRAL ASIA 0.97 1.05 1.05 1.07 
EUROPE 
 
0.59 0.59 0.59 1.14 
OCEANIA 
 
2.30 4.26 4.26 0.17 
 
 
The above regional figures include all 118 countries across all three data sources.  The 
‗OECD‘ and ‗AidData‘ columns represent adjustments (that is, replacing UNAIDS data with 
either OECD or AidData estimates) made only to those countries for which OECD or 
AidData data were available.  This gives an idea of how the overall picture changes when 
alternative data are used for the limited number of countries for which these are available.  
Red indicates overspending. 
 
Regionally, the results firmly show that Sub-Saharan Africa and Oceania are overspending.  
UNAIDS data holds that the Middle East is overspending, but only by 0.01 percentage points.  
Sub-Saharan Africa spends rather wildly out of proportion to disease burden and would need 
to reallocate approximately 40% of its spending to other diseases in order to spend 
proportionately.   Though there is large disagreement between UNAIDS and the other two 
data sources in the region, Oceania seems the biggest overspender by all accounts.  In the best 
case scenario (UNAIDS), it would have to reallocate 93% of AIDS spending to achieve 















    
North and Central America - which would have to increase spending by more than 50% - and 
Europe – which would have to nearly double its AIDS spending to achieve proportionality. 
 
The following regression reflects the trends evident in UNAIDS data and are a kind of 2008 
update of the figure provided by Nattrass and Gonsalves.  Both use WHO data for total health 
expenditure (though Nattrass and Gonsalves, as mentioned, include all private health 
expenditure), both use UNAIDS data for AIDS spending and both use DALY data from the 
same 2004 update.  The vertical axis measures that percentage of total health expenditure 
spent on AIDS for each country, while the horizontal axis measures that percentage of total 
DALYs accounted for by AIDS for each country.  OECD and Aiddata data indicate similar 
trends and are shown, along with trends for Sub-Saharan Africa, in Appendix 1.3. 
 
Figure 2.4: AIDS spend (% overall health spend) vs. AIDS DALYs (% overall DALYs), 2008 
(UNAIDS data) 
 spend (% overall health spend) vs. AIDS DALYs (% overall DALYs), 2data) 
 
*This anomalous result is discussed below 




olivi  sni  and Herzegovina 
Botswana 





C pe Verde 
Central African Republic 
Chad 
Chil  hi  Colo bi  
Congo 
Congo Dem. Rep. 
osta Ric  
Côte d'Ivoire 
Cr tb  ch epublic 
Djibouti 




st nia Fiji 
Gabon 
Gambia The 





H ng ry Indi  Ind ne iIra  
Kenya 
K w it
Kyrgyzstan Lao PDR 





M y i  
Mali 
arshall Islands M xic  i r es
old va ngoli  




Nicar gu  
Niger 
Nigeria 
P kistauP n ma Pa aguay Peili pin s R iRu si Federation 
Rwanda 
Saint Kitts and Nevis 
S T e nd Principe
Senegal 
S ych ll s in p r  l m I l s 
South Africa 
p ii L k  
St Vincent and the Grenadines 
w dtz rl dyri  
Tajikistan 
Thailand Ti or Leste 
Togo 
ong  Trinid d  To ago uvalu 
Uganda 
UkrU t Ki gdom 
V tu 
V z l







0 20 40 60 80 100 
%AIDS DALYS of total DALYs 
Fitted values 




















































    
Main findings: country-specific results 
 
Table 2.4 summarises the most important findings of the proportionality exercise: those at the 
country level.  Data from all three AIDS spending data sources are reported.  Though there 
are many to choose from, three key indicators have been selected that this author deems most 
helpful for interpretation of results.  Firstly, whether a country has over- or under-spent is 
indicated with either a tick (√) or a cross (X) respectively.  Secondly, that percentage of AIDS 
spending that would have to be increased or decreased in order for the proportionality 
condition to be satisfied is presented for each country.  Decreases are shown with a negative 
sign.  Thirdly, the dollar amount each country would have to increase or decrease spending by 
in order to satisfy proportionality is indicated.  Finally, those countries that are sensitive to 
choice between UNAIDS and OECD data by more than $5 million are underlined.  Blank 
spaces in the OECD column represent countries for which no OECD data were available.  
Blank spaces in the AidData column represent those countries for which no alterations or 






















    
Table 2.4: Country-specific proportionality results 














UN OECD AID 
 
UN OECD AID 
 
UN OECD AID 
AFRICA                         
SUB SAHARAN AFRICA                       
Angola 
 
X √ √ 
 
76.3 -0.2 -0.2 
 














116.4 -4.6   




-36.5 -36.6   
Burundi 
 
√ √ √ 
 
-75.3 -74.7 -74.9 
 
-19.6 -19.0 -19.2 
Cameroon 
 
X X X 
 
5.2 69.8 61.4 
 
2.1 17.3 16.0 




-2.5 -1.2   


















12.2 15.0   
Democratic Rep. of Congo √ √ √ 
 
-67.4 -60.8 -61.3 
 
-58.0 -43.5 -44.4 
Côte d'Ivoire √ 
   
-44.8 







   
48.8 






















21.9 20.9   
The Gambia √ √ √ 
 
-84.8 -77.9 -78.3 
 














-12.4 -6.6   
Guinea-Bissau √ √ √ 
 
-86.5 -80.1 -87.3 
 
-3.2 -2.0 -3.4 
Kenya 
 
√ √ √ 
 
-79.7 -65.9 -66.5 
 
-525.8 -259.6 -265.7 
Lesotho 
 
√ √ √ 
 
-35.3 -35.6 -36.0 
 
-28.7 -29.1 -29.6 
Madagascar √ √ √ 
 
-93.9 -94.5 -94.5 
 
-11.2 -12.5 -12.5 
Malawi 
 
√ √ √ 
 
-53.8 -67.8 -68.0 
 
-57.4 -103.9 -104.7 
Mali 
 
√ √ √ 
 
-87.6 -85.8 -85.9 
 
-35.4 -30.2 -30.5 
Mozambique √ √ √ 
 
-37.7 -57.9 -58.0 
 
-54.7 -123.9 -124.8 
Niger 
 
√ √ √ 
 
-88.2 -85.2 -86.5 
 
-11.0 -8.4 -9.4 
Nigeria 
 
√ √ √ 
 
-35.3 -37.5 -37.5 
 
-139.3 -153.0 -153.1 
Rwanda 
 
√ √ √ 
 
-70.8 -75.8 -75.8 
 
-78.5 -101.2 -101.2 




-0.1 -0.7   
Senegal 
 
√ √ √ 
 
-81.1 -78.9 -79.0 
 
-20.7 -18.0 -18.2 




-0.2 -0.1   
South Africa X X X 
 
127.4 120.6 119.1 
 
2157.5 2105.4 2093.7 
Togo 
 
√ √ √ 
 
-63.5 -27.6 -27.9 
 
-9.8 -2.1 -2.2 
Uganda 
 
√ √ √ 
 
-60.1 -55.3 -55.4 
 
-178.3 -146.2 -146.7 














-4.8 -4.7   
Morocco   √ √     -34.8 -19.4     -4.4 -2.0   
AMERICA                         
NORTH AND CENTRAL AMERICA                     




0.8 0.8   
Bahamas 
 















    










(millions 2008 US$) 
for proportionality 







-3.9 -3.1   
Cuba 
 
√ √ √ 
 
-59.2 -53.0 -53.4 
 







0.3 0.4   
Dominican Republic X X X 
 
190.6 123.0 110.7 
 
44.6 37.5 35.8 
El Salvador √ √ √ 
 
-28.1 -18.9 -19.0 
 











   
-57.8 



















15.9 14.2   
Nicaragua 
 
√ √ √ 
 
-81.6 -83.0 -83.1 
 
-12.2 -13.4 -13.5 
Panama 
 
X X X 
 
325.9 375.8 374.3 
 
44.4 45.8 45.8 
Saint Kitts and Nevis √ 
   
-85.8 








-0.3 0.8   




27.0 25.0   
SOUTH AMERICA                      
Argentina 
 
√ √ √ 
 
-24.1 -24.5 -24.5 
 
-60.1 -61.1 -61.2 
Bolivia 
 
√ √ √ 
 
-55.7 -66.1 -69.0 
 



































√ √ √ 
 
-18.9 -31.1 -31.3 
 
-1.8 -3.4 -3.4 
Peru 
 
X X X 
 
123.0 203.3 203.2 
 







42.8 42.7   
ASIA                         







-40.0 -45.2   
China 
 
√ √ √ 
 
-4.4 -6.2 -6.4 
 














-4.9 -4.9   
Malaysia 
 
X X X 
 
223.4 227.0 226.3 
 







-5.0 -5.01   
Philippines 
 
√ √ √ 
 
-92.6 -94.2 -94.2 
 




   
-28.7 










804.7 795.0   
Timor Leste √ 
   
-97.1 










-29.7 -7.5   
MIDDLE EAST                      
Iran 
 
X X X 
 
4.5 2.5 2.3 
 




   
63.3 

















-1.9 -2.1   
SOUTH AND CENTRAL ASIA                    
Afghanistan √ √ √ 
 
-99.9 -99.8 -99.9 
 
-3.2 -1.8 -3.1 
















    










(millions 2008 US$) 
for proportionality 























-7.6 -5.4   
India 
 
X X X 
 
97.6 69.0 68.9 
 
142.0 117.5 117.3 













-30.1 -10.9   
Pakistan 
 













-1.0 -0.6   
Tajikistan 
 






-5.9 -10.1 -10.1 











   
-39.5 












   
-90.0 










-9.5 -9.4   
Czech Republic √ 
   
-93.3 







   
-37.3 







   
-72.4 







   
-31.0 



















-11.6 -5.7   
Montenegro √ 
   
-35.9 







   
20.5 







   
32.9 




Russian Federation √ 
   
-33.8 







   
-77.0 







   
865.0 





   
6913.6 












-82.0 -89.0 -89.3 
United Kingdom √ 
   
-79.1 











-2.21 -0.58   
Marshall Islands √ 
   
-96.7 







   
-94.1 







   
-40.3 







   
-78.4 




Solomon Islands √ 
   
-97.3 







   
-97.0 







   
-97.6 






















According to UNAIDS data, 71% of countries (84 out of 118) overspend on AIDS relative to 
its share of their disease burden.  The use of OECD instead of UNAIDS data only switches the 
overspend/underspend conclusion for four countries: Angola (UNAIDS under by $24.2 
million, OECD over by $0.1 million), Botswana (UNAIDS under by $116.4 million, OECD 
over by $4.6 million), Grenada (UNAIDS under by $0.03 million, OECD over by $0.1 
million) and St. Vincent and the Grenadines (UNAIDS over by $0.3 million, OECD under by 
$0.8 million).  As one can see, however, this minor shuffling only changes the number of 
overspending countries by 2 – from 84 in UNAIDS data to 86 in OECD data.  Further, no 
switches occur when using AidData as opposed to OECD data.  The finding, thus, that over 
70% of countries overspend is robust across all three data sources.  The claim made by 
Bongaarts and Over (2010: 177) – that UNAIDS data underestimates the number of 
overspending countries – is correct in 2008, but an additional two countries is a very small 
win.     
 
Switching data sources does matter, however, for conclusions about how much reallocation 
needs to take place.  A total of 104 countries are sensitive to changes between UNAIDS and 
OECD data by more than $1 million, while 30 (underlined) are sensitive by more than $5 
million.  Of these, 12 countries are sensitive to changes by more than $10 million: 
 
Table 2.5: Countries sensitive to change in data source from UNAIDS to OECD by more 
than $10 million 
Table 2.5 - Countries sensitive to change in data source from UNAIDS to OECD data by more than $10 million 
OECD US$ Million Smaller(S)/Bigger(B) Cut(C)/Increase(I) than 
UNAIDS 
Kenya 266.20 SC India 24.59 SI 
Mozambique 69.26 BC Rwanda 22.72 BC 
South Africa 52.09 SI Vietnam 22.20 SC 
Malawi 46.55 BC Myanmar 19.20 SC 
Uganda 32.13 SC Cameroon 15.22 BI 
  
    
  
Angola 24.33 Switches category entirely   
Botswana 121.03 Switches category entirely   
  *SC or ‗smaller cut‘, for example, means that OECD data imply less money  


















It must be noted that the UNAIDS data for Kenya produce an anomalous result – namely, that 
119% of the country‘s total health expenditure is spent on AIDS.  This is clearly impossible, 
and in this case the OECD data (which posit an AIDS spending share of 71%) are perhaps to 
be preferred.  AidData data only deviate from OECD data by more than $1 million in 7 
countries: South Africa, Dominican Republic, Guinea-Bissau, Afghanistan, Niger, Cameroon 
and Kenya.  Of these, only South African figures deviate by more than $10 million, calling for 
an $11.71 million smaller increase in spending to reach proportionality than those of the 
OECD. 
 
All countries have been ranked in terms of their degree of over-spending and under-spending.  
It would be onerous to list specific ranks as they change between data sources, so full rankings 
are presented in Appendix 1.4 and only the following interesting results noted (rankings and 
figures refer to UNAIDS data unless otherwise stated).  Afghanistan, Vanuatu and Bangladesh 
are the top three biggest overspenders (relative to their health budgets and disease burdens) 
and would need to reallocate upwards of 99% of AIDS spending in order to reach 
proportionality.  Cape Verde, Madagascar and Guinea are the three highest relative 
overspenders in Africa, with reallocation figures upwards of 90%.  The three countries that 
would need to reallocate the most money are the United Kingdom ($733m), Spain ($706m) 
and Kenya ($526m).  The three corresponding top three African countries are Kenya, Uganda 
($179m) and Nigeria ($139m).  Switzerland is unquestionably the biggest relative 
underspender, and would have to boost AIDS spending by 6914% to reach proportionality.  It 
is followed by Sweden (865%) and Algeria (701%).  Algeria, Equatorial Guinea (617%) and 
Gabon (184%) are the top three relative underspenders in Africa.  South Africa is 
unanimously, and by an astounding margin, the country that requires the largest amount of 
extra AIDS spending to reach proportionality – all data sources imply spending increases of 
around $2.1 billion or 120%.  The next two countries requiring the most drastic increases are 
Switzerland ($1.03 billion) and Thailand ($804m).  The corresponding top three African 
underspenders are South Africa, Botswana ($116m, though OECD deems this country an 
overspender) and Ghana ($35m). 
 
Such rankings as have been referred to are interesting, but the most meaningful results are 
undoubtedly those that involve the countries with the highest AIDS burdens.  According to 
















lived in overspending countries in 2008.  This figure decreases by approximately 10 000 when 
one uses OECD data where available.  This represents approximately 54% of all HIV positive 
people contained within the dataset.  HIV population data are missing for 20 overspending 
countries but only 4 underspending countries (5 in OECD data).  54%, thus, is likely to be a 
significant underestimate.  The following are the results for the top 20 countries that contain 
the most HIV positive individuals: 
 
Table 2.6: Proportionality results – 20 countries most heavily affected by HIV 
 Table 2.6 - Proportionality results – 20 countries most heavily affected by HIV 
















      UN OECD AID   UN OECD AID   UN OECD AID   
1 South Africa X X X 
 
127.4 120.6 119.1 
 
2157.48 2105.39 2093.68 5600 
2 Nigeria 
 
√ √ √ 
 
-35.3 -37.5 -37.5 
 
-139.33 -153.04 -153.06 3200 
3 India 
 
X X X 
 
97.6 69.0 68.9 
 
142.05 117.46 117.32 2400 
4 Kenya 
 
√ √ √ 
 
-79.7 -65.9 -66.5 
 
-525.77 -259.56 -265.67 1400 
5 Mozambique √ √ √ 
 
-37.7 -57.9 -58.0 
 
-54.68 -123.94 -124.82 1300 
6 Uganda 
 
√ √ √ 
 
-60.1 -55.3 -55.4 
 
-178.32 -146.19 -146.73 1100 
7 Russian Federation √ 
   
-33.8 






√ √ √ 
 
-53.8 -67.8 -68.0 
 
-57.37 -103.92 -104.68 910 
9 China 
 
√ √ √ 
 
-4.4 -6.2 -6.4 
 












X X X 
 
5.2 69.8 61.4 
 















   
-44.8 






√ √ √ 
 
-82.0 -83.2 -83.2 
 
-82.03 -88.98 -89.32 350 
15 
Democratic Rep. of 
Congo √ √ √ 
 
-67.4 -60.8 -61.3 
 












√ √ √ 
 
-35.3 -35.6 -36.0 
 



















20 Ghana   X X     92.3 67.6     35.01 29.43   260 
 
 
65% (13) of these countries spend more on AIDS than its disease burden warrants (12 or 60% 
in OECD data).  Indonesia, Ukraine and Kenya need to reallocate the largest percentages of 
AIDS spending; while Kenya, Russia and Uganda need to reallocate the most money to 
















AIDS spending increases of 385% (UNAIDS) or 363% (OECD).  South Africa and India are 
next in line, both requiring an approximately two-fold increase in AIDS spending.  South 
Africa, Thailand and Brazil require the greatest monetary increases in AIDS spending in order 
to reach proportionality.   
 
When one considers the spending reallocations/increases required per HIV positive individual, 
the picture does not change significantly.  According to UNAIDS data Thailand ($1.463m 
UNAIDS, $1.446m OECD), South Africa ($0.385m UNAIDS, $0.376m OECD), and 
Botswana ($0.375m UNAIDS, $0.015m in overspending per person in OECD) need the 
most per person; while Kenya ($0.376m UNAIDS, $0.185m OECD), Russia ($0.279m 
UNAIDS, no OECD data) and Ukraine ($0.234m UNAIDS, $0.254m OECD) need to 
reallocate the most per HIV positive person.  The choice of data, as mentioned, affects the 
overspend/underspend conclusion for Botswana.   
 
One might be tempted from the above to conclude that the world is spending 
disproportionately ‗too much‘ on AIDS – after all, the majority of countries are.  This would, 
however, represent a kind of first-past-the-post framing of the problem: whichever side gets 
the most countries wins.  This author prefers another electoral system; one of proportional 
representation.  When the total amount of overspending is weighed against the total amount of 
underspending, an extremely interesting result arises.  According to UNAIDS data, the total 
amount for all overspending countries in excess of proportional spending is $3.84 billion.  The 
total amount falling short of proportional spending in underspending countries, however, is 
$5.29 billion.  The corresponding figures when OECD adjustments are made where possible 
are $3.65 billion and $5.01 billion respectively.  Put another way, there is approximately $1.44 
billion (or $1.43 billion) in global net underspending.  Though most countries overspend, in 




There is a global trend towards disproportionate overspending on AIDS relative to its disease 
burden.  The direction of the trend is not sensitive to choice of data source.  Most HIV positive 
individuals live in countries that overspend.  This conclusion, too, is not sensitive to choice of 
















conclusions, specifically for the 12 countries previously noted.  Further, while overspending is 
the norm, those countries that underspend typically do so quite vastly.  Indeed, tallying 
surpluses and deficits shows that there is approximately $1.4 billion more underspending than 
there is overspending.  South Africa illustrates this most vividly.  Even if all those countries 
that overspend were to reallocate their surpluses to South Africa, the country would still fall 
short of proportionality by approximately $700 million.   
 
Choice of data source      
 
Much has been made of the differences (or lack thereof) between OECD and UNAIDS data, 
but little guidance has been provided on which source to prefer.  The issue is not an easy one.  
OECD data provide a more thorough, official account of resources flowing from DAC donors.  
Moreover, statistical work carried out by the DAC is useful for long-term analysis of trends in 
donor spending.  This data does, however, come with a nine to twelve month lag and is ―not 
suited to real-time political resource decision-making, a purpose for which it is not intended‖ 
(UNAIDS, 2005: 3).  UNAIDS data, meanwhile, is specifically aimed at providing current, 
‗nimble‘ data (with a three to six month lag) that can be applied readily in rapidly changing 
policy and financial environments.  Many questions can‘t wait almost a year to be answered, 
and in these cases UNAIDS will be the obvious (and only) choice.  Moreover, the country-
level data it provides is a greater aid to decision-making than the OECD data, which is 
peppered with unspecified bilateral and regional allocations.  It must be remembered, 
however, that the country teams responsible for UNAIDS data collections may miss some 
donor funding flowing outside of government.   
 
Even given such gaps in UNAIDS data, in trying to account for all AIDS resource flows 
within a given country it should capture much funding from DAC as well as non-DAC 
members.  This may recommend it over OECD data.  While the 2010 Development 
Cooperation Report (OECD, 2010c) does explicitly mention ongoing cooperation in data 
collection efforts between the DAC and non-DAC donors, to date information on the extent of 
South-South cooperation is slim.  Some non-DAC members do report to the OECD - their net 
disbursements totaled $9.48 billion in 2008 (OECD, 2010c: 259) – but it is not clear how 
much of this went to AIDS.  Some $87.6 million was contributed to the Global Fund by 
















information.  It is not absolutely clear which official data source provides the most 
comprehensive picture of AIDS spending – this is, after all, why both have been reported.  
Since UNAIDS data are meant to include all AIDS spending that OECD data include, but not 
vice versa, it may be logical to assume that OECD data are more reliable in countries where its 
estimate exceeds that of UNAIDS.  Further, since UNAIDS data are meant to capture more 
spending than OECD data (because of non-DAC contributions), it may be logical to assume 
that UNAIDS data are more reliable in countries where its estimate exceeds that of the OECD.  
A guideline, albeit a loose one, could be to ‗pick the highest number‘. 
 
Getting an idea of where the official sources stand is important, but the AidData estimates are 
also helpful for a better understanding of the totality of AIDS funding.  Since little information 
is available on non-DAC donors anywhere, they – like the UNAIDS and OECD data – do not 
include funds flowing from potentially important South-South collaborations.  Still, it is useful 
to see that some projects not classified under ‗STD Control including HIV/AIDS‘ or ‗Social 
mitigation of HIV/AIDS‘ do seem to involve mainly AIDS components.  Whether it is 
appropriate to include these or not is up to the individual user.  Importantly, the steps taken in 
building the AidData database preempt accusations against OECD data of the type Bongaarts 
and Over leveled at UNAIDS data – namely, that they may miss a significant amount of AIDS 
spending.  Since the AidData adjustments did not make much of a difference, one can reject 
the claim that a significant amount of donor funds is being missed by the two AIDS-related 
CRS purpose codes.       
 
2.3 – Discussion and weaknesses 
   
The analysis conducted excludes some potentially important countries due to unavailability of 
either total health spending or AIDS spending data – Zimbabwe, Zambia, Namibia and 
Swaziland, for example.  Further, as has been mentioned, the measure of disease burden used, 
the DALY, incompletely captures the complexity of the AIDS virus.  It does not deal well 
with comorbidity and thus underestimates true affliction caused by the disease.  Infection with 
HIV increases one‘s chances of contracting TB, for example (Corbett et al, 2003; Goodman, 
1995).  Technically, if AIDS could be said to be the direct cause of 3% of TB cases, 3% of 
TB‘s DALYs should be included.  No such data exists, however.  There is also the problem of 
















Again, there is very little that can be done about this.  Finally, the many AIDS cases prevented 
by the initiatives enabled by existing AIDS funding have not been captured.  If effective 
prevention strategies are keeping the AIDS burden of disease low, optimal spending may 
appear as overspending. 
 
All these concerns are relevant, but do not belong to AIDS alone.  DALYs are incomplete, but 
they are at least consistently so.  There is little reason to imagine that they underestimate the 
burden of AIDS in ways that they do not in other, equally vicious conditions.  ART provides 
an exception to this rule, however.  Because those AIDS sufferers on ART suffer less 
disability (0.167) than those not on ART (0.505), AIDS DALYs in a given country will 
decline as more people are placed on ART.  Thus, if a country spends proportionally in one 
year and uses funding to expand treatment, it will ‗overspend‘ the next year because treatment 
has led to a decline in DALYs.  This leads to the absurd problem that if funding were made 
contingent on proportionality, it would lead to a perverse disincentive to expand ART.  
Ideally, the measure of proportionality used should be adjusted in such a way as to account for 
the presence of ART.  In the case at hand, however, it is perhaps fortunate that the latest 
DALY data available are for the year 2004 – a time when global ART coverage was minimal 
(approximately 12% [UNAIDS and WHO, 2005: 11]).  This problem is thus unlikely to affect 
results as much as it would in more recent years.  It should, however, be kept in mind when 
the current WHO update is complete and more recent DALYs are published.         
 
The felicity associated with using 2004 DALYs, unfortunately, stops at ART.  Because 2008 
and not 2004 expenditure is used, the above exercise tacitly ignores the effects of any 
developments in the relative disease burden of AIDS from 2004 to 2008.  This could affect the 
results for each country in one of two ways.  Firstly, if the AIDS disease burden has worsened 
relative to other conditions since 2004, they will underestimate the amount of AIDS spending 
required for proportionality.  In these cases, overspending will be less and underspending 
more dramatic.  Alternatively, if the burden of other diseases has worsened relative to the 
AIDS burden, results will overestimate the amount of AIDS spending required for 
proportionality.  In these cases, overspending will be more and underspending less dramatic.   

















In the extreme case of South Africa, it seems likely that the size of the epidemic, coupled with 
the vast funding deficit, may have led to a worsening of the AIDS burden relative to other 
conditions.  In other countries, however, it is more difficult to tell.  As noted in the beginning, 
past studies on proportionality found that AIDS has consistently received more funding per 
DALY than any other disease.  It may be reasonable, then, to assume that this surge in funding 
has actually led to an improvement (ie. decrease) of the AIDS disease burden relative to other, 
more underfunded diseases.  Unfortunately, without updated DALY data there is no way to 
tell either way.  Since DALYs rely on more than mere incidence levels, even calculating the 
changes in the spread of each disease won‘t provide an answer.  The question is whether 
burdens have reshuffled so much between 2004 and 2008 so as to switch the 
overspend/underspend conclusions for those countries that differ significantly from 
proportionality – these are, after all, the main focus.  Since deviations are often extreme, this 
author does not believe this is likely. 
 
As mentioned initially, it is important to recognize that the issue of proportionality is one 
talking point among many in the AIDS spending debate.  This analysis has not stepped into 
the important field of cost-effectiveness, which at least in principle allows for maximizing the 
effects on disease burden at the margin.  Then again, it is precisely because there is limited 
data for this kind of study and none at all at the international level that this paper has focused 
on proportionality.  It is this author‘s hope that clarity on proportionality will provide 
groundwork for future cost-effectiveness analysis.  Another issue not touched upon is that 
raised by those such Girard et al (2010) and Barry and Townsend (2010).  They contend that 
the real issue in the AIDS funding debate is not proportionality but insufficient global health 
spending - rather than cutting down on AIDS resources, they argue, efforts should be directed 
to increasing spending across the board.  This, however, does not address the question of 
where additional resources should be directed and which diseases need them most.  Again, 
clarity on proportionality can provide a good starting point for this.   
 
The analysis has also not ventured into the question of vertical (focused on a specific 
condition) versus horizontal (focused on building broader health systems) health programmes 
(see Ooms et al, 2008, in particular; as well as Nattrass and Gonsalves, 2010; Reddi and 
Leeper, 2010; Asiimwe et al, 2010; MacKeller, 2005; and Bongaarts and Over, 2010).  To the 
















analysis in this paper overestimates the share of funding exclusively directed towards AIDS.  
Many of the AIDS projects read through in the AidData database did contain reference to 
broader healthcare initiatives but, as mentioned, it was quite impossible to determine whether 
AIDS plays well with others in the health playground.  This is the one area, perhaps, that will 
provide the most fruitful avenue for further research. 
 
An issue that deserves some attention is that regarding the political realities of reallocating 
expenditure.  The shifting of any planned future expenditure from AIDS to other diseases or 
broader healthcare programmes should not be blind to issues of monitoring and 
accountability.  It is all well and good to say that more funds should be diverted to battling 
bilharzia, say, but who monitors the incidence of the disease?  How does one analyse whether 
prevention efforts are working?  Who is responsible for ensuring that infected rivers are 
clearly signposted?  Who gets fired when they are not?  In the absence of clearly defined, 
measurable targets and clear channels of responsibility, money shifted to other healthcare 
programmes may disappear into opaque management systems that fix few problems and even 
fewer people.  The 2004 World Development Report speaks at length of the importance of 
accountability to service delivery, and introduces an analytic framework for thinking about 
the concept involving five key elements: delegation, finance, performance, information about 
performance and enforceability.  The link between them is explained with a simple example: 
 
―In buying a sandwich you ask for it (delegation) and pay for it (finance). The 
sandwich is made for you (performance). You eat the sandwich (which generates 
relevant information about its quality). And you then choose to buy or not buy a 
sandwich another day (enforceability), affecting the profits of the seller‖ (World 
Bank, 2004: 47).  
 
Proper information and enforcement capabilities are required if proper performance is to 
come from finances delegated.   
 
The machinery of AIDS activism mentioned at the very beginning not only pieces money 
together, but also sounds loud sirens when money is being misallocated and misspent.  It has 
done so on many occasions, an apt example being the Treatment Action Campaign‘s 
constitutional court battle with the South African government over the latter‘s limited rollout 
















in any discussions about reallocation.  Nattrass and Gonsalves (2010) summarise the point 
well: 
 
―In the absence of easily measurable outputs and clear, politically feasible and 
sustainable mechanisms to hold government to account, funds can all too easily be 
misappropriated [De Renzio, 2006] or shifted away from priority health 
interventions—as was the case in Zambia when the TB program collapsed after 
being ―integrated‖ into the general health care system [Bosman, 2000]. AIDS 
spending, by contrast, can be linked to specific targets and has a constituency 
(treatment activists) with a strong incentive to hold governments 
accountable...Undercutting HIV funding, ostensibly in order to build a better health 
care system, could dismantle the most organized and effective health care consumer 
constituency in existence in developing countries‖ (2010: 175). 
 
This applies to other diseases and healthcare initiatives as well as to the components of AIDS 
spending itself.  The 2010 Global HIV Prevention Progress Report Card (GHPWG, 2010) 
notes that few prevention programmes have clear, well-defined targets or monitoring 
mechanisms.  Indeed, it states that ―analysis of data indicates that the world is doing a poor 
job of implementing sound, evidence-based, well planned programmes‖ (2010: 1).  Such 
evidence needs to be taken into account when calling for a greater focus on prevention versus 
treatment (see Over, 2008, for example), ostensibly in order to fast-track eradication of the 
epidemic.          
 
Finally, it must be noted that proportionality may not be useful in cases where health spending 
is extremely low in every sphere.  In such cases, it may be that a certain minimum of 
healthcare infrastructure needs to be put in place for the initiation of a coherent response to the 
AIDS epidemic.  Moreover, spending from a low base will have to gather momentum in one 
or a few areas until talk about reallocation will be meaningful.  It is impractical to suggest that 
a very poor country should concentrate on all things at once, from the first.  Despite these 
qualifications, it is very useful to see that certain countries – particularly South Africa, Brazil, 
Thailand, Kenya, Nigeria and Uganda – are not spending even remotely in line with their 
AIDS disease burdens.  In these countries, there is certainly space to examine spending 
allocations and, in extreme cases of disproportionate overspending, open the question of 
















2.4 - Conclusion 
 
The results generated do not solve the problem of precisely if, where and how much future 
spending should be reallocated within countries.  They do, however, lend a measure of clarity 
to a metric that has been, and doubtless will continue to be, used to argue on both sides of the 
AIDS funding debate.  In particular, we have seen that OECD and UNAIDS data do indeed 
produce different spending figures at the country level, and that choice of data source has very 
real implications for any exercise aimed at gauging how much money is really being allocated 
to each country‘s fight against AIDS.  Bongaarts and Over (2010: 76) were right to flag the 
issue (2010: 177), but their analysis was too cursory to support their implication that UNAIDS 
data are likely to underestimate AIDS spending.  The exercise conducted in this chapter has 
shown that the relationship between the two data sources is considerably more complex than 
these authors suggest.  Further investigation is required to determine why certain countries 
exhibit severe discrepancies.  Nattrass and Gonsalves (2010: 175), meanwhile, put forward 
arguments based on figures that, because of the massive increases in AIDS spending between 
2007 and 2008, are currently outdated.  The flat-lining of funding between 2008 and 2011 
means that the results presented in this study are far more relevant to present conditions.   
 
 























Chapter 3 - Critique of AIDSCost 
 
AIDSCost , the AIDS costing and projection model designed by Mead Over and Owen 
McCarthy and released by the Centre for Global Development, adds to the tool belt of those 
wishing to estimate the costs of global antiretroviral therapy (ART).  Not only is the model 
easy to use, but it also allows projections for a large number of countries with significant 
levels of HIV infection.  However, it remains important that those wishing to use this model 
understand the logical underpinnings and shortcomings thereof.  While its simplicity is 
laudable, its parsimony comes with various oversimplifications and misrepresentations that 
call into question its cost projections.  This is not merely a question of curiosity.  Mead Over 
has recently used the model to argue that, should the United States continue to support the 
expansion of ART in developing countries, the financial burden thereof will become 
overwhelming – there will arise a ‗ballooning entitlement‘, as shall be discussed in more 
detail later.  Over has argued that, in lieu of this, the United States should shift focus away 
from treatment and towards prevention.  Considering the gravity of the issue at hand – 
namely, the provision of life-saving drugs to multitudes of people by the world‘s largest 
AIDS donor – it is of vital importance that the reliability of Over‘s cost estimates be 
interrogated.   
 
This chapter will proceed as follows.  Section 3.1 contains a brief overview of the workings of 
AIDSCost.  Section 3.2 analyses the model‘s main shortcomings and recommends suitable 
alterations. Section 3.3 compares the model‘s outputs for South Africa with those of 
ASSA2003 for the period 2007-2016, in order to attain some measure of the former‘s quality.  
As ASSA2003 employs a large variety of data and is calibrated to fit actual trends in AIDS 
deaths by age, gender and race, it may be referred to as a kind of gold standard.  McCarthy 
and Over have openly solicited comparisons of their model with others, ASSA2003 among 
them (2009: 29). It is this author‘s hope that the following analysis will aid AIDSCost‘s 



















3.1 - The mechanics of AIDSCost 
 
AIDSCost actually comprises two programmes: AIDSProj and AIDSDif.  AIDSProj provides 
all the key outputs of concern to this investigation (incidence, prevalence, treatment costs and 
the like), while AIDSDif facilitates comparison between the costs and benefits of different 
AIDSProj scenarios.  Since AIDSDif is not relevant to this chapter, AIDSProj will henceforth 
be referred to as AIDSCost.  For ease of understanding, let the reader assume that he/she is 
looking at the world through the eyes of the model.  Fresh from the programming laboratory, 
it has been given its first job: to calculate the future global burden of ART.  To do this, it 
decides that it needs to track HIV positive individuals through a progression of states – being 
AIDS sick, needing first-line treatment and receiving second-line treatment, for example.  It 
approaches the problem in the following way: 
 
1.) How many new people are infected with HIV each year; in other words, how does 
a model like me estimate incidence?  I have data on total number infected for 
2007, but what about beyond that?  Let me assume that, each year, incidence will 
be some multiple of the incidence in the previous year but will not exceed it.  Let 
me create a variable that the user can adjust, incmult, with values between 0 and 1 
(1 being 100% of the previous year‘s incidence).      
 
2.) I now have the stock of HIV positive people each year, but need to calculate how 
many of these are actually AIDS-sick, ie. eligible for ART.  Let me define erate 
as the parameter that indicates what proportion (again between 0 and 1) of HIV 
positive people become newly AIDS-sick each year, and ndrate as the parameter 
that indicates what proportion of AIDS-sick not receiving treatment die each year.  
Those AIDS-sick that survive but do not receive treatment constitute unmet need 
for ART each year.   
 
3.) Next, I need to calculate how much of this need for ART is satisfied each year.  I 
thus create the parameter uptake with values between 0 and 1.  If uptake is 0.85, 
for example, in any given year 85% of AIDS-sick people not already on ART and 
needing treatment receive it.  I assume that no one is taken off of ART until they 
















is an extremely important and highly variable policy target, and so assign it no 
default.      
 
4.) I need to be more specific about treatment – after all, there is a massive difference 
in cost between first- and second-line treatment.  The number of those on their 
first year of first-line treatment is labelled a1, and is simply the number of those 
new to ART each year.  I recognise that the first year of first-line therapy is one in 
which treatment failure can be high.  I thus create adrate to capture the death rate 
on a1, and calculate the number of those on post-first-year-first-line therapy each 
year as a2.  This includes the number of the previous year‘s surviving a1 minus 
those a2 who have failed first-line therapy and thus become eligible for second-
line therapy.  Adrate2 gives this latter proportion (see Figure 3.2).  
 
5.) To calculate those on second-line therapy, I need to determine how many people 
who need it actually get it each year.  I have already seen that those that need 
second-line therapy are those that fail first-line therapy.  I define the proportion of 
these that are given this treatment each year as cvrg2.  The number of those on 
second-line therapy then becomes this proportion minus those who die on second-
line therapy each year, the latter being given by bdrate.   
 
We now have a basic idea of how AIDSCost works.  McCarthy and Over provide a small 




























Figure 3.1: Structure of the AIDSCost model (as per model manual) 
 
 
    
















































































The model presents users with the following interface and default values: 
 




The user is able to adjust each of the parameters above as he/she sees fit, while a previous 
screen allows for the tweaking of the uptake parameter.  The importance of this uptake must 
be stressed.  This is the only parameter that does not have a default value and is a pivotal 
input in determining the number of patients on, and thus the cost of, ART.  Note that uptake 
(the rate at which people who need ART, but are not already on ART, gain access to ART) is 
not the same as ART coverage (which includes the numbers already on ART both in the 
numerator and the denominator).  As we shall see, a positive uptake rate invariably tends to 
100% coverage over time.  This is because the model does not allow the user to specify a 
starting level of first-line coverage, nor does it allow for a target level of first-line coverage. 
Only second-line starting levels and targets can be specified.  It is also important to note that 
each of the above parameters stays constant over time.  Setting an uptake rate of 0.85, for 
example, commits the area in question (country, region or world) to meeting 85% of unmet 
need each year until the last year of projection.  Lastly, when estimating across different 
countries and regions, the model does not allow for variability in the parameters.  If different 
values of the parameters are required for different countries or regions, individual runs are 























Using the output data, AIDSCost then calculates the total cost of ART in region i and year j 
according to a simple cost function: 
 
                            
 
Where ART1 and ART2 are the number of people on first-line and second-line ART 
respectively, and       and       are the unit costs of the two treatments (including 
pharmaceutical and non-pharmaceutical costs).   
 
 
3.2 - Problems and areas for further research 
 
Exploring the mechanics of the AIDSCost model reveal a number of troubling issues, many of 
which have potentially catastrophic (the word is not used lightly) implications for the 




As mentioned above, AIDSCost does not allow the user to specify target overall coverage 
levels, only target uptake rates and second-line coverage targets.  Total coverage tends to 
100% over time.  This has to do with the fact that uptake is specified as a constant rate of need 
satisfaction amongst those not already on ART.  As this can be confusing, it is worth 
summarising the difference between ART coverage and ART uptake:        
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The coverage shortfall is given by unmet need for ART; as this tends to zero, total coverage 
tends to 100%.  In other words, if there is no unmet need everyone who needs ART gets it.  If 
one thinks back to the model diagram, one sees that unmet need must decline consistently 
over time.  This is because each year fewer people are infected (declining incidence) and thus 
fewer new people each year that need ART (since the number of AIDS sick is calculated as a 
constant proportion of those with HIV).  Moreover, some of those that need ART but don‘t 
get it die and do not form part of unmet need in the next year.  Put another way, since the 
level of satisfaction of need amongst those not on ART does not decline (being a constant 
proportion, uptake), as time passes we are satisfying a given percentage of a declining 
number.  Total ART coverage, thus, will tend to 100%.  Graphically, the process is depicted 
thus: 
 





While it is possible to specify an extremely low uptake rate that will effectively place 100% 
ART coverage outside of the 2050 projection range, this forces the user into a rather absurd 
trade-off (between limiting overall coverage and rapidly scaling up treatment) that is unlikely 
to present itself in the real world. 
 
The inability to set total coverage targets renders the model inappropriate for calculations 
involving countries like South Africa, where, for any given period, policy targets are stated as 








































to determine, ex ante, the appropriate values to assign to the parameters.  The costs of a target 
ART coverage level of 80% for the year 2015, for example, cannot be directly estimated.  
Rather, users must specify some target value of uptake and then read the corresponding total 
coverage level from the AIDSCost outputs.  Thus, in the comparison with ASSA2003 
(discussed in the next section), this author had to specify a number of uptake rates until the 
desired level of coverage (80%) by 2012 (the actual policy target) was reached.  While it is 
possible to reverse engineer the output and, in so doing, retrieve the correct coverage for the 
correct date, this process is time consuming and impractical.   
 
Another problem, perhaps due to the above, is that total ART coverage can expand in an 
unrealistic manner.  Again considering the forthcoming comparison to ASSA, total coverage 
made a jump from 27% in 2007 to 72% in 2008 (discussed in more detail below).  It is 
doubtful, especially given the need for measured budgetary planning over a number of years, 
whether real-world ART scale-up would be so sudden at the outset.  Further, it takes an 
extremely optimistic view of the ability of developing countries to roll out treatment - a 
problem likely to be exacerbated by the unwillingness of some individuals suffering from 
AIDS to go onto ART (see, for instance, Steinberg, 2008).   
 
Considering the above, the following changes are recommended for investigation by the 
model designers: 
 Adding adjustable target levels and rates of total ART coverage 
 Allowing for the direct adjustment of levels and rates of uptake of 1st line 
treatment 
 Allowing for coverage levels to remain constant beyond a certain date 
 Providing for a more gradual progression from initial rates to target rates of 


























McCarthy and Over (2009) assume that costs follow logistic functions of the following forms, 
and vary according to Gross National Income per capita: 
 




Source:  (McCarthy and Over, 2009: 7) 
 
However, there are a number of reasons to believe that these assumed relationships are too 
simple.  Firstly, in low-income settings, non-drug costs may be considerably higher than these 
curves suggest due to the costs of setting up previously nonexistent primary healthcare 
infrastructure.  Neglecting these costs is likely to lead to serious underestimation of ART 
rollout costs in very low income settings.  Secondly, it seems unlikely that costs are so neatly 
related to GNI per capita alone. Such a measure neglects the effects the size of the epidemic 
in a given country may have.  Large epidemics, even in middle income countries, could 
prompt the mobilisation of international civil society behind cost-lowering movements (eg. in 
South Africa), increase demand for generics and provide economies of scale (the latter issue 
















Kumaranayake [2008]) – all of which may contribute to lower per patient drug costs than 
AIDSCost would predict.   
 
Perhaps the most disconcerting assumption of AIDSCost is that regarding the way that costs 
change over time – the assumption, that is, that they do not change at all.  Future changes in 
the costs of ART are impossible to predict with any precision.  It is, however, unlikely that 
costs will not change over time.  In the case of Brazil, for example, there was significant 
variation in the costs of antiretrovirals (ARVs) between 2001 and 2005 (Nunn et al, 2007).  In 
the past, the entry of China and India as producers of ARVs has significantly lowered AIDS 
treatment costs.  ARV producers in countries such as Thailand, Brazil and South Africa, for 
example, rely heavily on raw materials sourced from these two countries (Grace, 2004).  As 
evidenced by this very debate, the epidemic is not yet under control and the drive to expand 
access to affordable treatment is still underway.   
 
The Clinton Health Access Initiative, for example, brings together pharmaceutical companies 
and governments to facilitate bulk orders of combination ARV therapies.  Since 2003, the 
initiative has negotiated pricing agreements with forty formulations of ARVs, together with 
eight companies, with seventy countries having access to reduced prices for these medicines 
(Clinton Foundation 2010: online).  Its work continues.  UNITAID‘s Medicines Patent Pool 
initiative, established in July 2010, is doing similarly admirable work in securing ARV price 
reductions for developing countries (see UNITAID, 2010: online).  As another example, on 
the 14
th
 of December 2010 South Africa‘s Department of Health announced a new tender for 
ARV drugs that will see costs decline significantly in the country (TAC, 2010: online).  Such 
examples are illustrative of how substantial price reductions can be achieved through better 
coordination and bargaining activities - without compromising the incentive to produce drugs.  
There seems to be no reason to believe that the market for ARVs has reached any kind of 
stable price equilibrium.  This is especially so since ART represents a lifelong commitment to 
treatment; since it preserves life, increased rollout is only going to provide bigger and bigger 
markets.   
 
Bongaarts and Over, however, assume that ―the effects of greater competition have largely 
been exhausted for the last generation of first-line drugs. The next generation will cost more 
because they are still under patent‖ (2010: 177).  This point was also made by Grace (2004).  
















last generation of drugs.  Mozambique has just unveiled plans to build the first public factory 
for ARVs in Africa, which is set to begin producing its own pills by 2012 (Timeslive, 2010: 
online).  Regardless of whether drug prices will rise or fall, the point is that they will change.  
AIDSCost cannot afford to ignore this. 
 
The following changes are recommended: 
 An option to discount or inflate prices should be added.  Price changes would 
have perhaps the most obvious and significant effect on the future cost-
effectiveness of ART.  Gauging the effects of different pricing assumptions, thus, 
is pivotal. 
 It would be helpful if users were allowed the option of inputting actual price data 
for individual countries and years rather than relying on assumed cost curves. 
Spectrum (another AIDS projection model), for instance, allows users to input 
national survey data through which modelled results are forced (Stover, 2004). 
Even a few actual numbers would increase the precision of the estimates. Further, 





AIDSCost assumes that incidence in each year is some constant multiple of incidence in the 
previous year.  The default value for incmult is 0.95, or a 5% decline in incidence each year. 
This, however, completely neglects any effect that ART might have on prevention.  Much 
evidence has been presented in support of the proposition that high ART coverage rates 
reduce HIV incidence – see, for example, De Cock et al (2009), Castilla et al (2005), 
Reynolds et al (2009), Janssen et al (2001) and Montaner et al (2006).  Mathematical 
modelling – by Blower and Farmer (2003), for example – has added further weight to this 
proposition.  In Brazil, between 2000 and 2001, widely available ART led to a 58% decline in 
new cases of HIV (Blower and Farmer, 2003); Granich et al (2009), meanwhile, posit that 
universal ART coverage in Sub-Saharan Africa would reduce incidence by 95%.  In May of 
2011, the United States International Institutes of Health announced the results of a trial 
(‗HPTN 052‘) that ―show[s] antiretroviral therapy to be 96% effective in reducing HIV 
transmission in couples where one partner has HIV [more than 1700 such couples were 

















While expanding ART coverage keeps people alive longer, thereby increasing HIV 
prevalence, treatment decreases viral load and thus renders each individual significantly less 
infectious.  De Cock et al give a succinct summary of the logic: 
 
―Transmission only occurs from infected persons who are numerically far fewer 
than HIV-negative susceptible persons; viral load is the greatest risk factor for all 
modes of transmission; ART [Antiretroviral Treatment] lowers viral load; 
prevention of mother-to-child transmission offers proof of concept; and there is 
observational evidence of reduced transmission from discordant heterosexual 
couples when the index partner is on ART‖ (2009: 488). 
      
Large-scale behavioural disinhibition – ie. when those on ART engage in more risky sexual 
behaviour because they perceive themselves to be less infectious – could counteract this 
effect.  Crepaz et al (2004), however, conducted a meta-analysis of the literature on the 
subject during the period 1996-2003 and found no evidence to suggest that people receiving 
Highly Active Antiretroviral Therapy (HAART) exhibited an increase in sexually risky 
behaviour.  Kennedy et al (2007), too, conducted a review of the relevant literature during the 
period 1990-2006 and, similarly, found no evidence that ART is associated with sexually 
risky behaviour in developing countries.  Though there is certainly space for more work in 
this area – Kennedy et al found only three primary articles that met their criteria – there is as 
yet little reason to believe that ART is firmly associated with behavioural disinhibition.  
Another issue is that the preventative effects of ART may depend on high and sustainable 
levels of coverage.  However, an assumption of universal ART coverage in AIDSCost‘s 
defaults still delivers the same decline in HIV incidence of 5% each year.  In light of the 
various pieces of research available on the relationship between ART and HIV incidence, the 
exclusion of any kind of dynamically estimated incidence variable represents a sizeable error.  






















Death rates vs. failure rates 
 
The AIDSCost manual gives a rather confusing explanation of adrate2.  Initially, adrate2 is 
described as ―the rate at which people fail first-line therapy and therefore become eligible for 
second-line therapy‖ (2009: 35).  When the model is run, however, the definition for adrate2 
is ―ART death rate during subsequent years on 1
st
 line‖.  To resolve this, consider the 
equation for post-first-year-first-line therapy (McCarthy and Over, 2009: 35): 
 
(1) 
                                  
 
The second term, meanwhile, is decomposed thus: 
 
(2) 
                                                     
 
Equation (2), using the first definition, merely states that the number of those from the post-
first-year-first-line ART group needing second-line ART is made up of those needy receiving 
second-line ART and those needy not receiving second-line ART.  This makes sense.  A 
quick look at these equations will confirm that adrate2 does not make sense if read as a 
straightforward death rate.  If it denoted such a rate, equation (1) would state that changes to 
a2 were made up of all those surviving first-year-first-line ART minus all those that died in 
a2.  If death were the only outflow from a2, however, no one would move to second-line 
therapy.  Patients, it seems, first fail post-first-year-first-line therapy and then either move on 
to second-line therapy or die.  Therefore, as long as cvrg2 is positive the number of patients 
that die will always be less than the number of those that fail post-first-year-first-line therapy, 
since the latter includes the former.  This is not a trivial error, as the incorrect definition is the 
one presented in both the model interface and model printout.  Since death rates and failure 
rates can be very different, users are likely to both misuse and misread AIDSCost.  It is 




















3.3 - Comparing AIDSCost to ASSA2003 
 
This section compares AIDSCost‘s outputs with those of the ASSA2003 model for South 
Africa.  ASSA2003 is an epidemiological model of the South African HIV/AIDS epidemic 
developed by the Actuarial Society of South Africa (ASSA) which can be used to project the 
course of the epidemic with and without ART.  It was released in 2006 but, because it used 
HIV prevalence data from Antenatal clinics up until 2003, it is known as ASSA2003.  The 
model makes use of a substantial amount of demographic data and has been calibrated to fit 
actual death rates by age, race and gender (see Nattrass, 2007).  As discussed below, its 
projections are consistent with national HIV surveys of population-level HIV prevalence and 
it is hence seen as a very reliable model of the South African AIDS epidemic.  Comparing the 
demographic projections of AIDSCost with those of ASSA2003 for South Africa is thus an 




In the tables below, the outputs of the AIDSCost model for South Africa for the period 2007-
2016 are compared to those of ASSA2003 (henceforth ASSA) for the same period.  Since 
AIDSCost allows for the adjustment of only a few parameters, and owing to discrepancies 
between the models, it is not possible to estimate both using precisely the same assumptions.  
ASSA, for example, does not differentiate between first- and second-line treatment, while 
AIDSCost does not allow for the specification of a target level for ART coverage (as 
previously discussed) as ASSA does.  The models, thus, are not directly comparable.  This, of 
course, does not change the fact that both will be used, and have been used, to leverage 
competing arguments that are of vital importance for policy-making (see, for example, Over, 
2008 and Nattrass and Geffen, 2005).  So even though the models‘ infrastructure is not 
directly comparable, their outputs – which are broadly the same – are.   
 
Considering the South African case allows for the use of ASSA as a reliable benchmark – as it 
was designed to apply only to South Africa, it uses much more specific data than AIDSCost.  
The model‘s estimates correlate well with actual survey data.  The 2008 Human Sciences 



















Figure 3.6 – ASSA2003 estimates for HIV prevalence in 2008 vs. HSRC’s national survey of 
HIV prevalence in 2008 
 
 
    Source: Dorrington (2009: 632) 
 
This point is echoed by Rehle and Shisana (2009: 634).  This consistency was also in 
evidence after the 2006 HSRC survey (see Gallo et al, 2006 and ASSA, 2006, for example).  
Kibel et al, meanwhile, go so far as to refer to the model as ―the gold standard‖ (2010:132).  
While, as with any model, there are issues – Dorrington (2009: 631), for example, mentions 
that the model may slightly overestimate male prevalence – it has proven itself robust in 
estimating the aggregated outputs that AIDSCost provides.  Insofar as AIDSCost‘s country-
specific outputs may be viewed as a proxy for its overall quality, and insofar as the 
assumption regarding ASSA‘s reliability holds, large discrepancies with ASSA can be seen as 
indicators of AIDSCost‘s flaws.         
 
The National Strategic Plan for HIV/AIDS calls for the provision of ‗adequate treatment‘ 
(which includes ART) to 80% of all those that need it by 2011 (Department of Health, 2007: 
14).  With half the year gone, however, it seems unlikely that this target will be met.  Thus, a 
target of 80% coverage, to be reached by 2012, is specified for both models.  This is still 
rather optimistic, but does capture the thrust of actual policy in South Africa.  Furthermore, it 
is prudent not to leave the analysis open to the charge of underestimating costs.  AIDSCost is 
run using all default assumptions except for those regarding target coverage for second-line 
treatment, which is specified as 80% (cvrg2) to be reached by 2012 (target year).  As 
mentioned, different uptake values were experimented with until the one that corresponded to 
















the unspectacular business of using Stata, one imagines that the fun would disappear after a 
very short while.  The correct value turned out to be 0.6, or 60% uptake each year.  The 
following results are of interest (the full results are included in Appendix 2.1): 
 
Table 3.1: AIDSCost cost projections 2007-2016 
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2007 27 5 153,333 281,111 25,555 316,709 135,032 
2008 60 17.5 744,001 403,266 27,267 836,357 144,078 
2009 70 30 472,320 1,034,416 31,834 1,098,410 168,210 
2010 75 42.5 395,778 1,403,958 49,100 1,312,007 259,444 
2011 78 55 372,498 1,692,127 79,497 1,505,111 420,062 
2012 80 80 362,978 1,948,515 132,850 1,685,078 701,979 
2013 82 80 356,352 2,186,366 193,874 1,853,641 1,024,430 
2014 84 80 349,747 2,408,937 261,899 2,011,080 1,383,874 
2015 86 80 342,507 2,616,860 336,366 2,157,378 1,777,357 
2016 87 80 334,576 2,810,166 416,741 2,292,516 2,202,059 
 
 
Note the ever-increasing overall ART coverage.   
 
ASSA is then used to generate projections of three different scenarios: 
 
1. ASSA 1 – 80% ART coverage reached by 2012.  This scenario most closely resembles 
AIDSCost‘s own assumptions regarding ART.  As noted, it is not possible to align all of 
the models‘ assumptions.  ASSA does, however, provide great flexibility and 
transparency with regard to its ART assumptions, and allows for the input of custom 
ART coverage levels – in this case, those given by AIDSCost.  Since AIDSCost does 
not allow for investigation of coverage rates before 2007 (where coverage was 27%), 
and since the analysis seeks to mimic the model‘s assumptions as closely as possible, 
























 Original ART 
coverage 
assumptions Tweaked 
2000 2 2 2009 No default 70 
2001 4 4 2010 No default 75 
2002 6 6 2011 No default 78 
2003 8 8 2012 No default 80 
2004 23 23 2013 No default 82 
2005 30 27 2014 No default 84 
2006 37 27 2015 No default 86 
2007 44 27 2016 No default 87 
2008 50 60    
 
It may seem puzzling that coverage was kept at 27% for 2005, 2006 and 2007. This 
has to do with the fact that AIDSCost, as mentioned, only gives information on 
coverage from 2007.  Since it is important to mimic AIDSCost‘s assumptions, this 
forces a guess at pre-2007 coverage rates.  Now, one could have used ASSA‘s defaults 
up until 2007 and then switched over to AIDSCost‘s.  ASSA‘s defaults, however, 
already exceed 27% total coverage in 2005, with coverage being 30% and 37% in 
2005 and 2006 respectively (the ASSA modeller‘s best estimate of what ART 
coverage was actually likely to be in those years).  Since it is better to avoid the 
unrealistic assumption that coverage will drop from 37% in 2006 to 27% in 2007 
(when the switch is made to AIDSCost‘s assumptions), coverage is kept constant at 
27% for 2005 and 2006.  There is little reason to replace ASSA‘s pre-2005 coverage 
with some other imagined figures.  Further, alternative options available (say, 24% in 
2005 and 26% in 2006) do not vary much from those which have been chosen.  This 
seems an imperfect but plausible estimation of AIDSCost‘s own pre-2007 coverage 
rates.  Beyond 2006, AIDSCost‘s exact coverage figures are used (using a 0.6 uptake 
value and 2012 uptake target). 
 
2. ASSA 2 – 80% target reached by 2012, gradual scale-up. This scenario employs 
AIDSCost‘s assumptions of ART coverage up to 2007 – as above - but then assumes 

















3. ASSA 3 (baseline) – Employs ASSA‘s default ART assumptions, but assumes 
gradual linear scaling up of ART from 50% in 2008 to a target of 80% in 2012, after 
which its level remains constant. This scenario arguably represents the best benchmark 
against which to measure the quality of AIDSCost, as it most clearly demonstrates the 
full strength of ASSA to model South African reality (Appendix 2.2). 
 




While the full results of these comparisons are included in Appendix 2.3, the following 
findings are of interest: 
 




Firstly, AIDSCost seems to posit an unrealistically high number of people on ART for almost 
all periods under consideration and compared to all ASSA scenarios.  Adam and Johnson 
(2009), for example, estimate that 568 000 individuals were enrolled in ART in 2008 
(ASSA‘s baseline projection was 504 548), whereas AIDSCost estimates this figure to be 1 


















































Secondly, AIDSCost posits that an extremely high proportion of those living with HIV are 
AIDS sick – ie. requiring ART.  ASSA‘s estimates for 2007 and 2008 are 675 431 and 726 
477 respectively.  AIDSCost‘s estimates for 2007 and 2008, by contrast, are 1 700 000 and 1 
961 734 respectively. It is these assumptions that feed into the extremely high numbers on 















































































Thirdly, AIDSCost seems to take a very optimistic picture of AIDS deaths, assuming them to 
decline drastically.  This is perhaps an indicator of its default death rates – 13% for first-year-
first-line ART, 4% for those that fail ‗subsequent years‘ first-line ART and do not receive 
second-line treatment, and 1% for second-line ART.  Cleary et al (2006), referring to a study 
undertaken in the Western Cape of South Africa, cite an 86.9% survival rate after 12 months 
of ART (irrespective of drug regimen), which seems more or less in line with AIDSCost‘s 
assumption.  Between 12 and 24 months, however, this rate drops to 83.4%, while between 24 
and 36 months it drops to 79.5% and between 36 and 48 months it drops to 76.2%.  In other 
words, relative to these numbers, AIDSCost does not assume sufficient numbers of people 
die.  Even assuming that its second-line death rates are plausible (Cleary et al‘s study included 
mostly first-line ART), those for first-line certainly don‘t seem to be.  As one can see, even 
controlling for the drastic increase in treatment coverage between 2007 and 2008 (ASSA1), 
ASSA‘s death estimates are far above AIDSCost‘s.  To again refer to costs, underestimating 
the tally of the dead will overestimate the costs of treating the living.    
 
The spike in the curve is peculiar.  Using the equation for total deaths given by McCarthy and 
Over (2009: 36), manual calculations were conducted and indicated that total deaths in any 
given year are a function of the previous year‘s treatment figures.  If the second-line death 
rate is 1% and in 2007 5000 people are on second-line treatment, total second-line deaths will 
be 50 in 2008.  It seems that the kink is a result of the massive amount of people flowing into 







































their deaths are recorded in 2009, deaths are temporarily boosted in this year.  It may seem 
counterintuitive that putting more people on ART could increase deaths, especially given the 
30% death rate among those not receiving treatment.  It must be remembered, however, that 
60% of one year‘s ‗unmet need‘ group are placed on treatment the next year.  This effectively 
takes the death rate of this group to 12% (only 40% do not receive treatment, while only 30% 
of these die).  In 2007, thus, there were roughly 1.2 million people in the ‗unmet need‘ group, 
but only 12% of these died in 2008.  In 2008, however, there were 744 000 people in their 
first year of first-line therapy (as opposed to 153 000 in 2007), 13% of whom died in 2009.        
 









2nd line Total 
2008 148,800 19,933 9,277 256 178,266 
2009 94,464 96,720 11,291 273 202,748 
 
It is also worth noting that the model‘s outputs incorrectly list the second-line coverage for 
2007 as 0%, when the death calculations clearly take it to be 0.175%.  Note that the 2008 
figure is also 0.175%, which is at odds with the otherwise constantly increasing levels of 
second-line coverage.   
 









































Lastly, AIDSCost‘s estimates regarding AIDS deaths affect HIV prevalence rates.  
AIDSCost‘s underestimate of AIDS deaths implies that more people each year are available to 
be classified as HIV positive.    
 
3.4 – Cost implications 
 
The difference in dollars 
 
The above gives us an idea of the discrepancies between the models‘ outputs, but how will 
these affect cost projections?  First, let us consider what happens when AIDSCost does what 
it was designed to do; namely, assign dollars to the disease.  Its cost assumptions for South 
Africa are as follows: 
 
Table 3.4: AIDSCost per patient per annum costs for South Africa (1000s 2006 US$) 
 
  1st line 2nd line 
ARV costs 245 4800 
Non-ARV costs 484 484 
Total 729 5284 
 
As data on second-line treatment is not presented in ASSA, AIDSCost‘s outputs are used to 
calculate ratios between first and second-line treatment in each year (Appendix 2.3) and 
multiply them by ASSA‘s annual estimates of the number of those on ART.  Again, this is 
done to mimic AIDSCost‘s own assumptions as closely as possible.  Next, the above costing 

























Figure 3.12: Projected ART costs for South Africa (1), 2007-2016 (1000s 2006 US$) 
 
 
  Year AIDSCost ASSA1 ASSA2 ASSA3(B) 
Cumulative costs 2016 23,284,823 11,769,091 10,211,377 11,563,967 
Percentage of AC 2016 100% 50.54% 43.85% 49.66% 
Cumulative costs 2012 8,582,484 4,004,145 3,328,950 4,107,696 
Percentage of AC 2012 100% 46.65% 38.79% 47.86% 
 
As can be seen, the ASSA baseline projection estimates the costs of expanding ART in South 
Africa to 80% by 2012 to be approximately half those estimated by AIDSCost at the end of 
2016.  The exaggeration is even more marked at the end of 2012.  Note that even ASSA1, the 
scenario that most closely mimics AIDSCost‘s assumptions, estimates costs that are far lower 
than those put forward by AIDSCost.  
 
Next, an alternative set of costs is considered.  These are based on Cleary et al‘s extensive 
four-year study of 1729 patients in the Western Cape area of Khayelithsa (2006).  The study 
presents quarterly costs per Markov state (differentiated by treatment regimen and stage of 
disease) that include clinic visits, days in hospital, ARV costs, Tuberculosis treatment and 
safety and monitoring laboratory costs (2006: 8).  Fortunately, these costs are also presented 
in 2006 US Dollars.  Cleary et al go into some detail regarding the different costs associated 
with patients of varying CD4 counts.  However, as neither ASSA nor AIDSCost offer any 












































detail.  Instead, costs are averaged across all first-line and second-line patients to arrive at the 
following annual estimates (AIDSCost‘s estimates are included for comparison):    
 
Table 3.5: Cleary et al - per patient per annum costs (‘000s 2006 US$) 
 
 










ARV costs 290.8 952 245 4800 
Non-ARV costs 808.2 468 484 484 
Total 1099 1420 729 5284 
 
AIDSCost‘s ARV costs for first-line treatment seem roughly in line with Cleary et al‘s, as do 
second-line non-ARV costs.  Second-line ARV costs, however, seem grossly exaggerated 
relative to Cleary et al‘s, while first-line non-ARV costs seem heavily underestimated.  The 
latter assumption seems to support the comments made in Section 3.2; namely, that non-ARV 
costs are likely to be higher than AIDSCost assumes in developing countries.  Tuberculosis 
may have a significant role to play in this.  People infected with the HIV/AIDS epidemic are 
at greater risk of tuberculosis (see, for example, Arbulu et al, 1993; Chaisson et al, 1987; 
Corbett et al, 2003; and Goodman, 1995) and, in countries where health resources are 
strained, the two diseases may develop alongside one another and add to treatment costs. 
 





























Figure 3.13: Projected ART costs for South Africa (2), 2007-2016 (1000s 2006 US Dollars) 
 
 









Cumulative costs 2016 24,924,199 12,463,001 10,767,360 12,307,560 
Percentage of AC Cleary 2016 100% 50% 43.20% 49.38% 
Percentage of AC 2016 107.04% 53.52% 46.24% 52.86% 
Cumulative costs 2012 10,672,933 4,935,362 4,103,167 5,078,061 
Percentage of AC Cleary 2012 100% 46.24% 38.44% 47.58% 
Percentage of AC 2012 124.36% 57.51% 47.81% 59.17% 
 
Again, AIDSCost overestimates cumulative costs by approximately 100% in 2016 and 
slightly more in 2012.  The ‗Percentage of AC‘ row denotes each scenario‘s costs as a 
percentage of AIDSCost‘s original cost estimates.  It is interesting to note that Cleary et al‘s 
costing assumptions imply greater cumulative costs than those of AIDSCost.  This has to do 
with the higher proportion of those on first-line treatment – Cleary et al‘s first-line costs are 
much greater than AIDSCost‘s.  Considering cumulative costs, however, obscures important 
dynamics in the projections.  Consider the following figure, which shows the AIDSCost and 
ASSA baseline cost projections for both sets of cost assumptions (‗AC‘ being AIDSCost‘s, 












































Figure 3.14: Total ART costs, Cleary et al costs vs. AIDSCost costs (1000s 2006 US$) 
 
 
   
One can see that, as time progresses and the proportion of those on second-line treatment 
grows, AIDSCost‘s massive second-line ARV costs push up its estimates. 
 
Implications for Over’s arguments 
 
In a 2008 paper, Mead Over used the AIDSCost model to argue that US-funded global AIDS 
treatment ―could grow to as much as $12 billion a year by 2016 – more than half of what the 
United States spent on total overseas development assistance in 2006‖ (2008: 1).  The latter 
figure is based on an ‗aggressive‘ uptake rate of 95%.  A figure of $4.5 billion applies to the 
historical uptake rate of PEPFAR (President‘s Emergency Plan for AIDS Relief), 17.9%.  
Over argues that, should treatment continue to expand, more and more of this funding will go 
toward so-called ‗entitlement spending‘, which refers to spending on those already receiving 
ART.  Since taking a person off ART is tantamount to unplugging them from life support, the 
US would risk severe damage to its reputation by cutting back on such spending.  In order to 
avoiding saddling itself with ballooning commitments it can‘t get rid of, to put it crudely, the 
US should shift focus away from treatment and toward prevention.  It is not the focus of this 
paper to critique the notion of ‗entitlement‘, and nor is it this author‘s place to voice concerns 
about the trivialisation of human life into the language of political expediency.  It is, however, 
of concern that the projected magnitude of these entitlements is based on all of AIDSCost‘s 












































are reliable.  This author is of the firm opinion that, in scenarios requiring careful examination 
of costs, AIDSCost is not to be trusted.   
 
3.5 - Conclusion 
 
Forming a clear idea of the future costs of ART represents the first step towards answering the 
vital (literally) question of the cost-effectiveness of ART.  McCarthy and Over‘s attempts to 
model these costs, thus, are laudable.  One would do well, however, to note that 
misinformation is often worse than no information at all, and that every model pretending its 
fair share of reality should be approached with similarly fair shares of critique and testing.  Its 
authors‘ intentions notwithstanding, the preceding analysis has shown that there is good 
reason to believe that AIDSCost, in its current incarnation, is not a sufficiently reliable 
yardstick against which to measure policy.  It produces outputs that reflect highly 
questionable assumptions, each of which feeds into multiple parameters and compounds 
problems of cost overestimation.  In the case discussed, that of South Africa, AIDSCost 
showed severe discrepancies with the country‘s leading AIDS projection model, ASSA2003, 
its outputs implying an overestimation of costs in excess of 100%.  The models do not merely 
disagree; they do not seem even to speak the same language.  This is no idiosyncrasy of 
pricing.  While it is true that South Africa is one among many countries, the flaws in the 
model have mostly to do with the way the number of those who need and are on treatment are 
calculated, not with country-specific cost assumptions.  Until such flaws are attended to, the 
debate on which costs to use in the model will remain peripheral.  AIDSCost needs to tinker 
on its spine before it begins choosing appendages.   
 
As noted, McCarthy and Over have solicited comparisons with other models, ASSA2003 
among them.  This is constructive and, through the preceding critique, this paper has 
attempted to provide workable suggestions for the improvement of their model.  It is curious, 
however, that Over made use of the model (in 2008) before these solicitations were made (in 
2009).  It is this author‘s opinion that, given the true gravity of the millions being weighed, 
using the model to support claims regarding the unmanageability of ART without its first 
being properly tested is both careless and irresponsible.  Further research is required to 
investigate whether AIDSCost performs better in countries other than South Africa.  Until 
then, however, its numbers regarding the ballooning ‗entitlement‘ will contain more than a 


















Talk, apparently, is cheap.  Some forms of it, however, can be very expensive if left to wander 
into influential ears.  This is especially so when such talk brandishes numbers that supposedly 
represent bits of truths about the world.  There is a lot of talk at the moment about whether 
AIDS funding should be cut back or increased, urged along its current path or dramatically 
reengineered.  Many people‘s lives literally depend on the funding AIDS receives; now more 
than ever, therefore, it is important that we obtain as much clarity as possible on the issues 
involved.  The exercises conducted have contributed to the clarification of two very topical 
issues in this debate: proportionality and AIDS cost modeling.  As we have seen, the precise 
implications of a country‘s standing in terms of proportionality are complex and largely 
unclear.  However, there is now, for the first time, a clear picture of where the world lies in 
terms of proportionality.  Debates will be ongoing about whether this picture deserves to hang 
prominently on the walls of the AIDS funding debate, but at least it has been put into focus.  
Considerable value lies within the raw tables generated in Chapter 1, quite apart from the 
limited analysis conducted in this paper.  The availability of more recent DALY and health 
expenditure data will doubtless call for new investigation, but this is likely to take some time.  
Final 2008 estimates for the latter were only released in March 2011, after all, and the DALY 
update currently underway involves complex calculation and data collection.  In the time 
being, the results presented above can provide guidance as to where diseases besides AIDS are 
likely to be badly underfunded.  More detailed investigation is urgently required to see which 
of these is in most need in each country.   
 
The focus on AIDSCost sheds revealing light on certain strong arguments made by one of its 
co-creators, Mead Over.  Such arguments have been put forward quite brazenly; if listened to, 
the already dim prospects of the millions awaiting AIDS treatment will darken.  Fortunately, 
there does not seem to be any reason why they should be listened to.  Models, even if 
understood to be partial and imprecise, need to deliver results that are at least vaguely in line 
with reality – or our best guess of it - in order for them to be useful.  AIDSCost fails to tow 
even this vague line, and it is thus this author‘s contention that it should be withdrawn from 
the public arena until it has been drastically redesigned.  Such worrying findings should 
remind those interested in the future course of the epidemic to approach AIDS models with a 
















attractive facades.  But regardless of how sophisticated, popular or easy-to-use they are, their 
interior mechanisms need to be thoroughly interrogated before they can be trusted.  It does not 
seem that we can trust the AIDSCost model.  Work should be ongoing to see if we should trust 


































Appendices  for Chapter 1  
Appendix 1.1 - Background data: AIDS spending (% total health spending) vs. AIDS DALYs (% all 
DALYs) 
Note on regional and world totals for OECD and AIDDATA: (1) include those countries for which only UNAIDS data is available, (2) include regional figures not 
specified by country, eg. ‘Sub-Saharan Africa, regional’ 
HIV population totals for World and Sub-Saharan Africa taken directly from UNAIDS 2010 Global Epidemic Update 
 
 AIDS spending, public and 






HIV SPEND% VS DALY% 
 Overspend
, Y/N? 
 Health expenditure (millions 
2008 US$) 
DALYs 

































10824.71 33400   1.16 1.19 1.19 3.46                     
                                        
AFRICA 4414.19 4567.76 4594.60     11.94 12.35 12.42 10.49   Y Y Y             
SUB SAHARAN AFRICA 4390.28 4512.64 4539.18 22400   18.39 18.90 19.01 11.32   Y Y Y             
Angola 31.77 56.10 56.12 190 
 
1.40 2.48 2.48 2.47 
 
N Y Y 
 
2264.58 0.00 2264.58 12469.91 308.31 










144.05 0.01 144.06 3530.51 105.44 













903.47 893.87 451.41 










334.53 1.50 336.03 7402.20 254.13 
Burundi 26.06 25.41 25.60 180 
 
29.48 28.75 28.96 7.28 
 
Y Y Y 
 
60.40 28.00 88.41 4587.63 334.08 
Cameroon 39.97 24.75 26.05 590 
 
13.74 8.51 8.95 14.45 
 
N N N 
 
281.42 9.54 290.97 7969.03 1151.38 
Cape Verde 2.57 1.28 







55.51 0.00 55.51 85.16 0.18 










33.79 2.63 36.41 2273.33 303.06 










271.24 8.10 279.34 5889.20 347.66 










146.35 0.00 146.35 1296.76 211.35 
Congo Dem. Rep. 85.96 71.46 72.44 315 
 
17.68 14.70 14.90 5.76 
 
Y Y Y 
 
463.92 22.26 486.18 37312.69 2149.07 









   










   
52.04 0.00 52.04 280.00 25.78 










277.09 0.00 277.09 267.08 19.55 










21.23 0.00 21.23 1195.35 59.98 










166.91 0.00 166.91 400.22 80.83 
Gambia The 4.99 3.43 3.49 15 
 
15.62 10.74 10.94 2.37 
 
Y Y Y 
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Health expenditure (millions 
2008 US$) 
DALYs 
    
 
UNAIDS OECD AIDDATA 
  




























918.61 42.27 960.88 7530.46 571.63 










28.45 0.85 29.30 3929.56 111.56 
Guinea-Bissau 3.65 2.47 3.87 21 
 
22.32 15.12 23.71 3.01 
 
Y Y Y 
 
7.16 9.18 16.34 925.43 27.89 
Kenya 659.87 393.66 399.77 1400 
 
119.25 71.14 72.25 24.24 
 
Y Y Y 
 
466.42 86.91 553.33 14720.22 3567.46 
Lesotho 81.31 81.70 82.16 280 
 
87.84 88.26 88.75 56.81 
 
Y Y Y 
 
78.39 14.18 92.57 809.20 459.73 
Madagascar 11.95 13.24 13.26 23 
 
3.93 4.36 4.36 0.24 
 
Y Y Y 
 
291.57 12.32 303.88 6466.05 15.49 
Malawi 106.72 153.27 154.03 910 
 
53.16 76.35 76.73 24.58 
 
Y Y Y 
 
157.82 42.92 200.74 7574.92 1862.20 
Mali 40.39 35.18 35.54 77 
 
17.41 15.16 15.32 2.16 
 
Y Y Y 
 
231.98 0.00 231.98 7065.87 152.53 
Mozambique 144.95 214.21 215.08 1300 
 
36.04 53.25 53.47 22.44 
 
Y Y Y 
 
345.38 56.85 402.23 9655.50 2166.82 
Niger 12.46 9.90 10.91 60 
 
6.84 5.44 5.99 0.81 
 
Y Y Y 
 
181.44 0.71 182.15 9995.23 80.57 
Nigeria 394.66 408.38 408.40 3200 
 
9.67 10.01 10.01 6.26 
 
Y Y Y 
 
4072.75 8.73 4081.48 77690.31 4860.25 
Rwanda 110.81 133.53 133.56 160 
 
35.34 42.58 42.59 10.32 
 
Y Y Y 
 
211.10 102.47 313.57 5404.42 557.49 
Sao Tome and Principe 0.09 0.75 







5.69 3.70 9.39 50.67 0.04 
Senegal 25.57 22.86 23.02 56 
 
5.93 5.30 5.34 1.12 
 
Y Y Y 
 
419.13 12.11 431.24 4481.87 50.18 
Seychelles 0.57 0.50 







28.86 6.72 35.58 13.83 0.14 
South Africa 1694.00 1746.09 1757.79 5600 
 
17.91 18.46 18.58 40.72 
 
N N N 
 
9035.87 423.67 9459.54 20988.18 8545.40 
Togo 15.37 7.75 7.79 120 
 
25.08 12.66 12.71 9.16 
 
Y Y Y 
 
45.43 15.85 61.28 2539.88 232.74 
Uganda 296.65 264.52 265.07 1100 
 
46.94 41.85 41.94 18.72 
 
Y Y Y 
 
241.03 390.97 632.00 14145.83 2648.56 
NORTH AFRICA 23.91 22.95 22.95     0.18 0.18 0.18 0.23   N N N             










8037.24 2.42 8039.66 5215.39 19.75 










3345.88 7.17 3353.05 13317.61 10.76 










1714.58 0.00 1714.58 5030.63 24.05 
AMERICA 1739.88 1779.05 1782.21     1.11 1.13 1.13 1.57   N N N             
NORTH/CENTRAL 
AMERICA 
522.97 549.57 551.91     1.16 1.22 1.23 1.87   N N N             
Antigua and Barbuda 0.33 0.26 

















   
238.30 3.00 241.30 59.48 4.83 










1868.43 18.63 1887.07 532.44 4.52 
Cuba 46.62 40.48 40.86 6.7 
 
0.65 0.56 0.57 0.26 
 
Y Y Y 
 
7189.00 0.00 7189.00 1567.48 4.15 
Dominica 0.18 0.03 







14.06 0.00 14.06 10.91 0.34 
Dominican Republic 23.42 30.52 32.29 56 
 
2.03 2.65 2.80 5.91 
 
N N N 
 
963.69 188.25 1151.94 1986.41 117.35 
El Salvador 39.23 34.82 34.84 33 
 
4.94 4.39 4.39 3.56 
 
Y Y Y 
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Y/N? 
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2008 US$) 
DALYs 
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Grenada 0.48 0.64 

















   
899.80 64.81 964.61 2730.49 61.30 










517.17 14.52 531.69 1341.05 60.96 










29956.60 0.00 29956.60 15192.74 142.97 
Nicaragua 14.91 16.11 16.21 6.4 
 
4.44 4.79 4.82 0.82 
 
Y Y Y 
 
325.22 10.91 336.14 941.34 7.68 
Panama 13.63 12.20 12.24 20 
 
1.17 1.05 1.05 4.99 
 
N N N 
 
1161.20 1.00 1162.20 466.60 23.30 
Saint Kitts and Nevis 1.49 






   
19.27 0.00 19.27 8.63 0.09 
St Vincent and the 
Grenadines 
1.63 0.46 







18.83 0.00 18.83 22.21 1.54 










591.47 0.48 591.95 260.15 18.48 
SOUTH AMERICA 1216.92 1211.71 1212.53     1.08 1.08 1.08 1.45   N N N             
Argentina 248.77 249.83 249.93 110 
 
1.38 1.38 1.38 1.05 
 
Y Y Y 
 
17354.40 699.71 18054.11 5985.45 62.56 
Bolivia 5.39 7.04 7.71 12 
 
1.14 1.49 1.63 0.51 
 
Y Y Y 
 
459.03 12.57 471.60 2301.26 11.65 










60907.31 1336.05 62243.36 35896.05 485.19 










5630.99 276.54 5907.53 2095.36 13.11 




















   
1230.00 120.00 1350.00 2288.10 35.99 
Paraguay 9.30 10.95 10.98 12 
 
2.26 2.67 2.67 1.84 
 
Y Y Y 
 
403.80 7.02 410.82 974.73 17.90 
Peru 41.06 30.19 30.20 76 
 
1.17 0.86 0.86 2.60 
 
N N N 
 
3431.14 90.62 3521.76 4764.20 123.85 
Venezuela 71.72 71.81 







7545.41 658.06 8203.47 4217.56 58.87 
ASIA 1116.55 1170.94 1173.66     0.71 0.74 0.74 1.02   N N N             
FAR EAST ASIA 801.27 810.43 811.29     0.67 0.68 0.68 0.99   N N N             










148.60 72.93 221.53 5002.99 268.27 
China 323.83 330.11 330.83 740 
 
0.35 0.36 0.36 0.33 
 
Y Y Y 
 
92529.45 0.00 92529.45 200524.24 671.26 










6286.58 1.83 6288.42 53248.83 40.75 










37.02 41.17 78.20 1627.74 2.40 
Malaysia 24.29 24.02 24.07 97 
 
0.57 0.57 0.57 1.85 
 
N N N 
 
4211.77 23.90 4235.67 3682.09 68.28 










157.78 4.64 162.42 520.10 0.25 
Philippines 6.58 8.39 8.46 6.8 
 
0.30 0.38 0.38 0.02 
 
Y Y Y 
 










   
2202.85 5.31 2208.15 450.60 2.23 










8200.78 45.09 8245.88 12841.71 1578.90 
Timor Leste 1.83 






   
57.56 15.49 73.04 284.66 0.21 
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MIDDLE EAST 49.99 47.05 47.12     0.42 0.39 0.39 0.41   Y N N             
Iran 36.01 36.69 36.76 91 
 
0.45 0.46 0.46 0.47 
 
N N N 
 
7908.83 22.09 7930.92 12029.07 57.06 
Kuwait 4.70 






   
2203.64 0.00 2203.64 257.22 0.89 










1224.52 6.89 1231.41 720.05 4.81 
Syria 1.99 2.21 







583.30 0.00 583.30 2511.97 0.25 
SOUTH AND CENTRAL 
ASIA 
265.29 284.99 286.79     0.97 1.05 1.05 1.07   N N N             
Afghanistan 3.24 1.75 3.07 
  
1.12 0.61 1.06 0.00 
 
Y Y Y 
 
277.71 10.75 288.45 18437.13 0.22 










195.64 6.19 201.83 570.29 2.19 




















   
830.60 35.37 865.96 39993.13 7.82 










343.44 0.38 343.82 709.84 0.85 
India 145.59 170.18 170.32 2400 
 
0.64 0.75 0.75 1.26 
 
N N N 
 
17307.02 5477.13 22784.14 305111.89 3851.90 
Kyrgyzstan 8.80 13.61 13.83 7.5 
 
5.45 8.44 8.58 0.14 
 
Y Y Y 
 
141.87 19.39 161.26 1188.50 1.62 










43.41 18.30 61.71 13710.57 589.50 
Pakistan 14.19 22.48 22.49 93 
 
1.15 1.82 1.82 0.25 
 
Y Y Y 
 
1237.02 0.00 1237.02 40560.76 101.57 










724.68 16.37 741.04 4668.77 3.79 
Tajikistan 6.18 10.35 10.36 8.3 
 
7.76 12.99 13.01 0.32 
 
Y Y Y 
 
70.80 8.86 79.66 1616.83 5.15 
EUROPE 3258.19 3263.62 3263.96     0.59 0.59 0.59 1.14   N N N             




















   
37636.27 233.65 37869.92 1341.35 2.39 
Bosnia and Herzegovina 2.76 3.86 

















   
2117.24 16.08 2133.31 1426.12 0.61 










4628.76 0.00 4628.76 697.73 0.07 









   










   










   










   
7736.97 189.82 7926.79 1814.37 0.58 
Macedonia 3.66 4.77 4.78 
  
0.80 1.04 1.04 0.03 
 
Y Y Y 
 
457.16 1.69 458.85 340.62 0.12 
Moldova 12.87 7.02 







326.35 2.77 329.11 820.04 3.24 
Montenegro 0.60 






   










   










   
8769.25 8.21 8777.46 3842.18 11.42 
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31819.44 525.93 32345.37 794.27 4.82 
Ukraine 100.00 106.96 107.30 350 
 
1.45 1.55 1.56 3.23 
 
N N N 
 
6884.87 1.71 6886.58 11200.42 361.82 









   
191933.33 9294.44 201227.78 7718.34 20.15 
OCEANIA 5.53 10.27 10.27     2.30 4.26 4.26 0.17   Y Y Y             










97.48 1.52 98.99 146.09 0.44 
Marshall Islands 0.58 






   
20.70 0.00 20.70 13.65 0.01 
Micronesia 0.35 






   
30.52 0.08 30.60 16.47 0.01 
Nauru 0.08 






   
5.21 1.43 6.64 2.60 0.02 
Palau 0.06 






   
15.30 0.69 15.99 3.46 0.00 
Solomon Islands 0.60 






   
32.13 0.51 32.64 88.75 0.04 
Tonga 0.21 






   
10.91 0.38 11.28 14.66 0.01 
Tuvalu 0.05 






   
2.87 0.00 2.87 2.61 0.001 
Vanuatu 1.09 0.67 







20.39 0.76 21.15 37.33 0.01 
 
 
Unspecified regional expenditure (millions of 2008 US$) 
 
  OECD AIDDATA   OECD AIDDATA 
Africa, regional 32.18 32.48 Far East Asia, regional 3.12 3.14 
North of Sahara, regional 0.21 0.21 Middle East, regional 0.25 0.25 
South of Sahara, regional 
127.93 128.45 
West Indies, regional (North and 
Central America) 12.06 12.06 
America, regional 17.77 17.77 Europe, regional 3.49 3.49 
North & Central America, regional 14.55 14.55 States Ex-Yugoslavia 0.03 0.03 
South America, regional 0.61 0.61 Oceania, regional 6.78 6.78 
Asia, regional 28.47 28.47 Bilateral, unspecified 1485.23 1485.99 
Central Asia, regional 3.66 3.66 
   South & Central Asia, regional 2.96 2.96 
   South Asia, regional 0.74 0.74 

















Appendix 1.2 - Examples of the way AidData was coded for the purposes of this study 
  
Directed towards AIDS not captured by AIDS-related CRS purpose codes  AIDS as one among several project goals 






        
CRS 
purp. 
code CRS p. name CRS id 
  
Fredskorpset 
Through this project the partners aim to strengthen their relations, organise young people, and use sports as a tool for 






SCIAF - Income 
Generation and Health 
Support for People 
Living with HIV/AIDS 




  Advocacy HIV/AIDS 
Advocacy on HIV and AIDS, travel to participate in seminars, prepare information materiel for campaigns and support 
initiatives. 








THE PROJECT AIM TO CONTRIBUTE TO THE FIGHT AGAINST HIV/AIDS AND TO PROMOTE HEALTH AND LIFE 
CONDITIONS OF THE POPULATION IN NYANZA ZONE 
12191 Medical services 2007000148 
  
Disaster Prevention and 
Climate Change 
Mitigation 2008-2009 
1) Empowerment to prevent/mitigate disasters such as floods droughts and hiv/aids 2) Fulfillment of right to food through 









Specific Project Objectives: 1) Sustainable sources of basic food and income for vulnerable households 2) Community 





   
 
  
Local Cooperation Fund 
(LCF) in Kenya 
Environmental Education and Action. The project will promote the use of puppetry as a viable means of enhancing 
learning_ promoting creativity and innovativeness_ developing social skills and team work to alleviate weakness in 
teaching and learning in schools. It will concentrate on environmental education and action_ civics and citizenships_ 


























        
CRS 
purpose 
code CRS p. name CRS id 
  
Frame agreement with 
NGO (Frikyrklig 
samverkan FS rf) 
Social center_ Education & recreation center_ Suriname. Cources in capacity building for women in the slum with 
education regarding healt_ HIV/AIDS_ family life and family violence. Personal counceling and coaching. 
16050 
Multisector aid for 




U.S. Peace Corps In-
Country Funding 
U.S. Peace Corps In-Country Funding for On Board Strength of 73.  On Board Strengthincludes Trainees, 
Volunteers, and Peace Corps Response (formerly Crisis Corps) Volunteers.  Peace Corpsvolunteers work primarily 
in the areas of agriculture, business development, education, environment,health and HIV/AIDS and youth. 
43010 Multisector aid 2008026523 
  
Frame agreement with 
NGO (World Vision) 
Kituntu Integrated Community Development Project. The objective of the programme is to improve the quality of life 
of 19_769 people of Kituntu sub-county. Access to quality primary and secondary education and adult literacy will be 
increased. Access to better health services and hygiene/sanitation will be improved and both health and socio-
economic impact of HIV/AIDS at individual_ household and community levels mitigated. Household Food Security 
and resilience and community capacity to manage their own development will be improved. 




Sudan - Emergency HC 
in East - Plan 2008 
Plan will provide emergency health assistance to communities still affected by the conflict in eastern Sudan, 
especially IDPs or refugees forced to flee their homes.  It will specifically aim to save the lives of women and children 
through the provision of Emergency Obstetric Care - effectively providing trained medical staff, appropriate 
equipment and supplies, and a referral system.  Awareness raising will be undertaken around reproductive health, 
family planning, HIV/AIDS, sexually transmitted infections, gender-based violence, and traditional practices which 
can be harmful, such as female genital mutilation and early marriage.  Plan expects to reach an estimated 210,000 






CAR - WFP PRRO 
10189.2 
CAR - WFP PRRO 10189.2: Since 2003, the Central African Republic (CAR) has been characterized by recurrent 
insecurity. The security situation in CAR continued to worsen in 2007 with continuous clashes between rebels and 
regular troops. The humanitarian needs in the country drastically increased leading to more than 1 million conflict-
affected people in the Northern regions of the country. Ongoing insecurity has interrupted the agricultural cycle, 
seeds and other inputs to production, which are lacking, with a consequent dramatic decrease in agricultural 
production and an erosion in people#s coping capacity.Basic needs of conflict and disaster affected communities in 
developing countries are metExpected Outcomes: The specific objectives of the Protracted Relief and Recovery 
Operation (PRRO 10189.1) are to (i) protect the livelihoods of food-insecure target groups in post-conflict zones; (ii) 























Appendix 1.3 - Proportionality regressions: World and Sub-Saharan Africa (different data sources) 
Vertical axis: Percentage of total health expenditure spent on AIDS.  Horizontal axis: Percentage of total DALYs accounted for by AIDS 
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UNAIDS OECD AIDDATA 
  
UNAIDS OECD AIDDATA 
  
UNAIDS OECD AIDDATA 
Afghanistan 1 1 1 
 
Philippines 23 18 18 
 
Spain 45 43 43 
Vanuatu 2 3 3 
 
Myanmar 24 36 37 
 
Bosnia and Herzegovina 46 31 32 
Bangladesh 3 2 2 
 
Sao Tome and Principe 25 4 4 
 
Central African Republic 47 48 48 
Mongolia 4 5 5 
 
Indonesia 26 23 23 
 
Burkina Faso 48 44 44 
Laos 5 7 7 
 
Bulgaria 27 25 25 
 
Burundi 49 49 49 
Tuvalu 6 8 8 
 
Moldova 28 35 36 
 
Greece 50 50 50 
Kyrgyzstan 7 6 6 
 
Niger 29 30 28 
 
Rwanda 51 45 45 
Solomon 
Islands 8 10 10 
 
Fiji 30 52 54 
 
Armenia 52 47 47 
Timor Leste 9 12 12 
 
Mali 31 29 30 
 
Democratic Rep. of Congo 53 56 56 
Tonga 10 13 13 
 
Guinea-Bissau 32 37 27 
 
Egypt 54 55 55 
Syria 11 11 11 
 
Saint Kitts and Nevis 33 28 31 
 
Togo 55 74 74 
Marshall Islands 12 14 14 
 
The Gambia 34 42 42 
 
Sri Lanka 56 62 62 
Tajikistan 13 9 9 
 
Ukraine 35 32 33 
 
Uganda 57 60 60 
Macedonia 14 15 15 
 
Nicaragua 36 33 34 
 
Cuba 58 61 61 
Cape Verde 15 24 24 
 
Senegal 37 40 40 
 
Chile 59 57 57 
Croatia 16 16 16 
 
Azerbaijan 38 34 35 
 
Guatemala 60 59 59 
Georgia 17 22 22 
 
Kenya 39 54 53 
 
Bolivia 61 53 51 
Micronesia 18 19 19 
 
Benin 40 46 46 
 
Malawi 62 51 52 
Madagascar 19 17 17 
 
United Kingdom 41 39 39 
 
Côte d'Ivoire 63 63 63 
Guinea 20 26 26 
 
Palau 42 41 41 
 
Nauru 64 64 64 
Czech Republic 21 21 21 
 
Pakistan 43 27 29 
 
Belgium 65 65 65 
Eritrea 22 20 20 
 
Cambodia 44 38 38 
 



















     
(2) Underspenders 
    
 
UNAIDS OECD AIDDATA 
  
UNAIDS OECD AIDDATA 
  
UNAIDS OECD AIDDATA 
Estonia 67 67 67 
 
Switzerland 1 1 1 
 
Ghana 19 23 22 
Montenegro 68 68 69 
 




over 86th over 
Lesotho 69 69 68 
 
Algeria 3 4 4 
 
Kuwait 21 24 23 
Nigeria 70 66 66 
 
Equatorial Guinea 4 5 5 
 
Venezuela 22 25 25 
Seychelles 71 75 75 
 
Thailand 5 7 7 
 
Djibouti 23 26 26 
Morocco 72 78 78 
 
Bahamas 6 8 8 
 
Brazil 24 28 28 
Russian Federation 73 70 70 
 
Panama 7 6 6 
 
Belarus 25 27 27 
Hungary 74 72 72 
 




over 84th over 
Singapore 75 73 73 
 
Malaysia 9 10 10 
 
Romania 27 29 29 
El Salvador 76 79 79 
 
Dominican Republic 10 18 19 
 
Poland 28 30 30 
Vietnam 77 82 82 
 
Gabon 11 14 14 
 
Chad 29 20 20 
Argentina 78 76 76 
 
Trinidad and Tobago 12 16 16 
 
Lebanon 30 15 15 






Dominica 13 2 2 
 
Mexico 31 31 31 
Costa Rica 80 81 81 
 




over 77th over 
Paraguay 81 71 71 
 
South Africa 15 19 18 
 
Cameroon 33 21 24 
Ecuador 82 80 80 
 
Peru 16 11 11 
 
Iran 34 32 32 
China 83 83 83 
 
Congo 17 13 13 
     Honduras 84 85 85 
 
India 18 22 21 



















Appendices  for Chapter 2  
Appendix 2.1 - AIDSCost projections 2007-2016 
AIDSCost with tweaks: 2
nd
 line coverage level (80%) and target year (2012). All cost figures are in thousands of 2006 US Dollars 
 























# 2nd line 
ART  
2007 4,000,000 1,240,001 459,999 27 5,700,000 432,857 1,700,000 350,000 153,333 281,111 25,555 
2008 3,992,857 787,200 1,174,534 60 5,954,591 411,214 1,961,734 178,266 744,001 403,266 27,267 
2009 3,964,857 659,630 1,538,570 70 6,163,057 390,653 2,198,200 202,748 472,320 1,034,416 31,834 
2010 3,919,375 620,831 1,848,836 75 6,389,042 371,120 2,469,667 164,667 395,778 1,403,958 49,100 
2011 3,859,364 604,964 2,144,122 78 6,608,450 352,564 2,749,086 151,713 372,498 1,692,127 79,497 
2012 3,787,398 593,920 2,444,343 80 6,825,661 334,936 3,038,263 135,352 362,978 1,948,515 132,850 
2013 3,705,720 582,911 2,736,592 82 7,025,223 318,189 3,319,503 135,374 356,352 2,186,366 193,874 
2014 3,616,280 570,844 3,020,583 84 7,207,707 302,280 3,591,427 135,705 349,747 2,408,937 261,899 
2015 3,520,769 557,627 3,295,733 86 7,374,129 287,166 3,853,360 135,859 342,507 2,616,860 336,366 
2016 3,420,651 543,420 3,561,483 87 7,525,554 272,808 4,104,903 135,740 334,576 2,810,166 416,741 





























2007 451,741 0 0 0 451,741 316,709 100 0.0 316,709 135,032 
 2008 980,435 622,887 542,376 55 438,059 293,981 45 0.175 836,357 144,078 
 2009 1,266,620 540,534 344,321 27 922,299 754,089 73 0.3 1,098,410 168,210 
 2010 1,571,451 578,300 288,522 18 1,282,929 1,023,485 82 0.425 1,312,007 259,444 
 2011 1,925,173 574,552 271,551 14 1,653,622 1,233,560 86 0.55 1,505,111 420,062 
 2012 2,387,057 504,497 264,611 11 2,122,446 1,420,467 89 0.8 1,685,078 701,979 
 2013 2,878,071 507,310 259,781 9 2,618,290 1,593,860 91 0.8 1,853,641 1,024,430 
 2014 3,394,954 508,567 254,965 8 3,139,989 1,756,115 92 0.8 2,011,080 1,383,874 
 2015 3,934,735 508,341 249,687 6 3,685,048 1,907,691 94 0.8 2,157,378 1,777,357 


















Appendix 2.2 - ASSA2003 vs. AIDSCost 
 
Year AIDSCost ASSA1 ASSA2 ASSA3 AIDSCost ASSA1 ASSA2 ASSA3 AIDSCost ASSA1 ASSA2 ASSA3 
  HIV+, not AIDS sick*     Unmet need ART**     # on ART*** 
2007 4,000,000 4,826,839 4,826,839 4,871,134 1,240,001 591,801 591,801 546,114 459,999 305,154 305,154 360,479 
2008 3,992,857 4,847,552 4,847,552 4,942,828 787,200 620,839 620,839 530,429 1,174,534 383,933 383,933 504,548 
2009 3,964,857 4,963,371 4,883,760 5,007,241 659,630 513,516 601,596 501,486 1,538,570 599,628 501,415 661,441 
2010 3,919,375 5,081,511 4,937,253 5,073,573 620,831 415,077 550,815 456,697 1,848,836 833,299 651,379 832,455 
2011 3,859,364 5,186,479 5,008,192 5,144,224 604,964 338,633 479,711 401,109 2,144,122 1,057,517 827,368 1,012,951 
2012 3,787,398 5,275,640 5,095,831 5,220,683 593,920 281,841 396,380 338,817 2,444,343 1,262,114 1,023,452 1,199,016 
2013 3,705,720 5,350,069 5,198,724 5,303,602 582,911 240,109 306,564 272,996 2,736,592 1,443,532 1,234,661 1,387,754 
2014 3,616,280 5,413,810 5,279,377 5,367,779 570,844 207,210 253,774 233,920 3,020,583 1,603,788 1,413,032 1,546,129 
2015 3,520,769 5,469,862 5,342,934 5,417,788 557,627 179,690 221,784 209,874 3,295,733 1,745,265 1,562,759 1,678,065 
2016 3,420,651 5,520,372 5,393,211 5,456,962 543,420 155,555 201,930 194,611 3,561,483 1,870,507 1,687,813 1,787,321 
             Year AIDSCost ASSA1 ASSA2 ASSA3 AIDSCost ASSA1 ASSA2 ASSA3 AIDSCost ASSA1 ASSA2 ASSA3 
  # living with HIV     New infections     Adults needing ART^     
2007 5,700,000 5,502,269 5,502,269 5,515,866 432,857 498,654 498,654 496,102 1,700,000 675,431 675,431 644,733 
2008 5,954,591 5,574,029 5,574,029 5,611,719 411,214 491,338 491,338 486,386 1,961,734 726,477 726,477 668,890 
2009 6,163,057 5,641,567 5,623,507 5,690,735 390,653 478,507 482,936 477,408 2,198,200 678,196 739,747 683,495 
2010 6,389,042 5,725,750 5,667,694 5,759,844 371,120 467,174 474,051 468,866 2,469,667 644,239 730,441 686,271 
2011 6,608,450 5,816,653 5,716,289 5,825,223 352,564 458,332 465,477 461,207 2,749,086 630,174 708,097 680,999 
2012 6,825,661 5,906,350 5,775,058 5,891,374 334,936 451,866 457,606 454,592 3,038,263 630,710 679,226 670,691 
2013 7,025,223 5,990,197 5,846,944 5,961,315 318,189 447,359 450,631 449,023 3,319,503 640,128 648,220 657,713 
2014 7,207,707 6,066,443 5,924,980 6,031,168 302,280 444,222 446,273 445,564 3,591,427 652,633 645,604 663,389 
2015 7,374,129 6,135,221 5,999,014 6,094,700 287,166 441,911 443,502 443,355 3,853,360 665,358 656,080 676,912 
2016 7,525,554 6,197,337 6,065,149 6,149,932 272,808 440,157 441,757 441,951 4,104,903 676,965 671,938 692,969 
Corresponding ASSA variables and calculations: 




















Year AIDSCost ASSA1 ASSA2 ASSA3 AIDSCost ASSA1 ASSA2 ASSA3 
  % coverage - ART     Prevalence^^       
2007 27.0 27.0 27.0 44.0 11.8% 11.4% 11.4% 11.5% 
2008 60.0 60.0 37.6 50.0 12.3% 11.5% 11.5% 11.6% 
2009 70.0 70.0 48.2 57.5 12.7% 11.6% 11.6% 11.7% 
2010 75.0 75.0 58.8 65.0 13.0% 11.7% 11.6% 11.7% 
2011 78.0 78.0 69.4 72.5 13.4% 11.8% 11.6% 11.8% 
2012 80.0 80.0 80.0 80.0 13.8% 11.9% 11.7% 11.9% 
2013 82.0 82.0 80.0 80.0 14.1% 12.0% 11.8% 12.0% 
2014 84.0 84.0 80.0 80.0 14.4% 12.1% 11.9% 12.0% 
2015 86.0 86.0 80.0 80.0 14.6% 12.2% 11.9% 12.1% 
2016 87.0 87.0 80.0 80.0 14.8% 12.2% 12.0% 12.1% 
         
 
AIDSCost ASSA1 ASSA2 ASSA3 
    Year AIDS deaths       
    2007 350,000 398,450 398,450 371,691 
    2008 178,266 394,937 413,018 378,256 
    2009 202,748 365,143 409,717 378,806 
    2010 164,667 346,746 396,330 373,728 
    2011 151,713 338,767 377,508 365,095 
    2012 135,352 337,837 356,417 354,515 
    2013 135,374 340,670 343,139 348,865 
    2014 135,705 344,798 342,615 351,582 
    2015 135,859 349,004 347,600 357,575 
    2016 135,740 353,441 354,706 364,525 
    Corresponding ASSA variables and calculations: 


















































2nd line Proportion 







2007 459,999 153,333 281,111 25,555 33.33% 61.11% 5.56% 
2008 1,174,534 744,001 403,266 27,267 63.34% 34.33% 2.32% 
2009 1,538,570 472,320 1,034,416 31,834 30.70% 67.23% 2.07% 
2010 1,848,836 395,778 1,403,958 49,100 21.41% 75.94% 2.66% 
2011 2,144,122 372,498 1,692,127 79,497 17.37% 78.92% 3.71% 
2012 2,444,343 362,978 1,948,515 132,850 14.85% 79.72% 5.43% 
2013 2,736,592 356,352 2,186,366 193,874 13.02% 79.89% 7.08% 
2014 3,020,583 349,747 2,408,937 261,899 11.58% 79.75% 8.67% 
2015 3,295,733 342,507 2,616,860 336,366 10.39% 79.40% 10.21% 
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